PMID- 1718101 OWN - NLM STAT- MEDLINE DA - 19911029 DCOM- 19911029 LR - 20080213 IS - 0514-7166 (Print) IS - 0514-7166 (Linking) VI - 38 IP - 5 DP - 1991 Jul TI - Protective activity to murine experimental brucellosis conferred by monoclonal antibody ISS/32 anti-B. abortus. PG - 397-400 AB - The protective properties of the monoclonal antibody ISS/32 anti-B. abortus were estimated by splenic infection with B. abortus 544. Five groups of Balb/c mice were used: two groups, previously vaccinated with a 45/20 antigen and a-LPS antigen, were challenged after 30 days intravenously by inoculation of 2.10(5) cells of B. abortus 544, one group was challenged with the same dose of B. abortus 544 preincubated with MAb-ISS/32 and another one with B. abortus 544 incubated with negative serum; the fifth group infected with B. abortus 544 only served as control. The results, expressed as an index of splenic infection, show significant protective properties of monoclonal antibody ISS/32. The infection index in the MAb-ISS/32 group of mice was a bit lower than in B. abortus 45/20 vaccine group. AD - Istituto Superiore di Sanita, Roma, Italia. FAU - Adone, R AU - Adone R FAU - Ciuchini, F AU - Ciuchini F FAU - Pistoia, C AU - Pistoia C FAU - Marcon, G AU - Marcon G FAU - Piccininno, G AU - Piccininno G LA - eng PT - Journal Article PL - GERMANY TA - Zentralbl Veterinarmed B JT - Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B JID - 0331325 RN - 0 (Antibodies, Bacterial) RN - 0 (Antibodies, Monoclonal) RN - 0 (Epitopes) SB - IM MH - Animals MH - Antibodies, Bacterial/immunology MH - Antibodies, Monoclonal/*immunology MH - Brucella abortus/*immunology MH - Brucellosis/*immunology MH - Epitopes/immunology MH - Mice MH - Mice, Inbred BALB C EDAT- 1991/07/01 MHDA- 1991/07/01 00:01 CRDT- 1991/07/01 00:00 PST - ppublish SO - Zentralbl Veterinarmed B. 1991 Jul;38(5):397-400. PMID- 2185782 OWN - NLM STAT- MEDLINE DA - 19900612 DCOM- 19900612 LR - 20041117 IS - 0736-2293 (Print) IS - 0736-2293 (Linking) VI - 13 DP - 1990 TI - Vaccination against Brucella. PG - 147-68 AB - Vaccination has played an enormous role in reducing brucellosis in many countries. It is certain to continue to be the preeminent factor in control of the disease in others. The search for an ideal vaccine continues. Live vaccines have proved to be superior to inactivated products. They are effective, inexpensive, and immunity is more persistent. The disadvantages of postvaccinal antibodies can be minimized by reduction of previously recommended doses and through use of supplemental diagnostic tests. These procedures now make entire population vaccination of great practical significance with many advantages over limited use of the strains 19 and Rev. 1. Adult animal vaccination should be much more extensive in many countries. A live B. suis strain 2 vaccine developed in China deserves much additional evaluation, including use in swine, for which no satisfactory vaccine exists. It is generally agreed that cell-mediated responses are the dominant aspect of immunogenesis. However, the correlates that have frequently been used--dermal hypersensitivity and lymphocyte stimulation in vitro--appear to be poor indices of cell-mediated immunity in brucellosis. Many studies have shown that postvaccinal antibodies do not predict subsequent immunity. There is a great need for simple in vivo or in vitro methods to measure CMI. While vaccination of humans may be useful in control of brucellosis in some high-risk occupations, the ultimate success is dependent upon reduction of this very important zoonosis in natural hosts. This is most effectively accomplished by widespread use of vaccination. AD - Department of Infectious Diseases, College of Veterinary Medicine, University of Florida, Gainesville 32610. FAU - Nicoletti, P AU - Nicoletti P LA - eng PT - Journal Article PT - Review PL - UNITED STATES TA - Adv Biotechnol Processes JT - Advances in biotechnological processes JID - 8305187 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Animals, Domestic MH - *Brucella Vaccine MH - Brucellosis/*prevention & control MH - Brucellosis, Bovine/prevention & control MH - Cattle MH - Disease Models, Animal MH - Humans MH - Vaccination/veterinary RF - 73 EDAT- 1990/01/01 MHDA- 1990/01/01 00:01 CRDT- 1990/01/01 00:00 PST - ppublish SO - Adv Biotechnol Processes. 1990;13:147-68. PMID- 3106273 OWN - NLM STAT- MEDLINE DA - 19870612 DCOM- 19870612 LR - 20031114 IS - 0003-1488 (Print) IS - 0003-1488 (Linking) VI - 190 IP - 8 DP - 1987 Apr 15 TI - Antibodies in calves on feed supplemented with chlortetracycline after vaccination with Brucella abortus strain 19. PG - 1002-3 AB - Twenty dairy heifers each consumed 350 mg of chlortetracycline/day in their feed. Four tests were performed on serum specimens from these and 20 control calves after vaccination with Brucella abortus strain 19. The numbers of positive test results on the card test and mean titers on the tube and rivanol agglutination and complement-fixation tests were compared in the 2 groups. Using the rivanol and complement-fixation tests, there were differences in the mean titers at weeks 5 and 6 after vaccination, but by week 10, differences were not found. The results suggest that addition of low concentration of chlortetracycline in feeds have minimal effects on postvaccinal serologic reactions determined after strain-19 inoculation. FAU - Nicoletti, P AU - Nicoletti P FAU - Mason, R M Jr AU - Mason RM Jr FAU - Tehrani, J AU - Tehrani J LA - eng PT - Journal Article PL - UNITED STATES TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 RN - 0 (Antibodies, Bacterial) RN - 57-62-5 (Chlortetracycline) SB - IM MH - Agglutination Tests/veterinary MH - *Animal Feed MH - Animals MH - Antibodies, Bacterial/*analysis MH - Brucella abortus/immunology MH - Brucellosis, Bovine/immunology/*prevention & control MH - Cattle MH - Chlortetracycline/*therapeutic use MH - Complement Fixation Tests/veterinary MH - Female MH - Food, Fortified MH - Vaccination/*veterinary EDAT- 1987/04/15 MHDA- 2001/03/28 10:01 CRDT- 1987/04/15 00:00 PST - ppublish SO - J Am Vet Med Assoc. 1987 Apr 15;190(8):1002-3. PMID- 3619804 OWN - NLM STAT- MEDLINE DA - 19870911 DCOM- 19870911 LR - 20031114 IS - 0005-0423 (Print) IS - 0005-0423 (Linking) VI - 64 IP - 4 DP - 1987 Apr TI - Monitoring of dairy herds for Brucella abortus infection when prevalence is low. PG - 97-100 AB - A total of 2,698 dairy herds were surveyed in 1981-1982 in New South Wales and north eastern Victoria in a review of the methods used to monitor them for the presence of Brucella abortus. The methods used to monitor dairy herds were testing of all breeding cows over 1 year of age using the rose bengal test (RBT) and complement fixation test (CFT), the bulk milk ring test (BMRT), and testing of blood samples collected at abattoirs using the RBT and CFT. The surveyed herds had at least one whole herd test, and BMRT was done at regular intervals in the period of the survey. Of the 99 (3.7%) herds that reacted to the BMRT, 91 (3.4%) herds had false positive reactions and 8 (0.3%) herds were declared infected on follow-up herd testing. False-positive reactions were obtained in 22 herds on more than one occasion. Common causes of false positive reactions to the BMRT were thought to be previous vaccination with Strain 19 and sampling in very early or late lactation. Of the 98 (3.63%) herds that reacted to the whole herd serological tests, 80 (2.96%) herds had false-positive reactions and 18 (0.67%) herds were declared infected. Strain 19 vaccination was thought to be an important cause of false-positive reactions. Fifty-three (2.0%) herds showed suspicious reactions on abattoir monitoring but none was declared infected on follow-up testing. Of the 18 herds with infected or equivocal status, the BMRT identified?(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Rolfe, D C AU - Rolfe DC FAU - Sykes, W E AU - Sykes WE LA - eng PT - Journal Article PL - AUSTRALIA TA - Aust Vet J JT - Australian veterinary journal JID - 0370616 RN - 11121-48-5 (Rose Bengal) SB - IM MH - Abattoirs MH - Animals MH - Australia MH - Brucellosis, Bovine/*diagnosis/epidemiology MH - Cattle MH - Complement Fixation Tests MH - False Positive Reactions MH - Rose Bengal/diagnostic use EDAT- 1987/04/01 MHDA- 1987/04/01 00:01 CRDT- 1987/04/01 00:00 PST - ppublish SO - Aust Vet J. 1987 Apr;64(4):97-100. PMID- 3922342 OWN - NLM STAT- MEDLINE DA - 19850619 DCOM- 19850619 LR - 20031114 IS - 0005-0423 (Print) IS - 0005-0423 (Linking) VI - 62 IP - 2 DP - 1985 Feb TI - Use of an enzyme-linked immunosorbent assay in a bovine brucellosis eradication program. PG - 49-52 AB - An enzyme-linked immunosorbent assay (ELISA) was developed and was compared with the complement fixation test (CFT) in a bovine brucellosis eradication program. The ELISA detected significantly more reactors than the CFT in both strain 19 vaccinated infected herds (1.79% versus 1.14%) and non-vaccinated infected herds (4.2% versus 3.59%) but not in either vaccinated or non-vaccinated brucella-free herds. The specificity for both tests in brucella-free herds was greater than 0.998. The specificity and sensitivity of the ELISA were compared with those of 3 other tests (the Rose Bengal test; the indirect haemolysis test [IHLT] and the CFT) on serum from 151 animals cultured at slaughter. The calculated specificity of the ELISA in this infected group was lower than for both the CFT and the IHLT (0.58 versus 0.67 versus 0.75). The sensitivity however was much greater (1.0 versus 0.73 versus 0.71). The value of the ELISA when used in an eradication program is discussed. FAU - Cargill, C AU - Cargill C FAU - Lee, K AU - Lee K FAU - Clarke, I AU - Clarke I LA - eng PT - Journal Article PL - AUSTRALIA TA - Aust Vet J JT - Australian veterinary journal JID - 0370616 RN - 0 (Antibodies, Bacterial) SB - IM MH - Animals MH - Antibodies, Bacterial/analysis MH - Australia MH - Brucella abortus/immunology MH - Brucellosis, Bovine/immunology/*prevention & control MH - Cattle MH - Complement Fixation Tests MH - *Enzyme-Linked Immunosorbent Assay MH - *Immunoenzyme Techniques EDAT- 1985/02/01 MHDA- 1985/02/01 00:01 CRDT- 1985/02/01 00:00 PST - ppublish SO - Aust Vet J. 1985 Feb;62(2):49-52. PMID- 3935591 OWN - NLM STAT- MEDLINE DA - 19860218 DCOM- 19860218 LR - 20061115 IS - 0377-0168 (Print) IS - 0377-0168 (Linking) VI - 12 IP - 2 DP - 1985 Jun TI - The instability of Brucella abortus strain 45/20 and a note on significance of using an unstable rough strain in the diagnosis of bovine brucellosis. PG - 120-5 AB - The serum agglutinin titres of six heifers experimentally inoculated with live Br. abortus strain 45/20 were similar to those produced in six bullocks inoculated with virulent Br. abortus strain 544. However, the agglutinin response appeared slowly and disappeared earlier in the heifers than in the bullocks. It is concluded that Br. abortus strain 45/20 is an unstable strain, could revert to the smooth form and become highly agglutinogenic in non-pregnant heifers. The significance of using an unstable rough strain of Br. abortus vaccine in the diagnosis of bovine brucellosis is briefly discussed. FAU - Chukwu, C C AU - Chukwu CC LA - eng PT - Comparative Study PT - Journal Article PL - TAIWAN TA - Int J Zoonoses JT - International journal of zoonoses JID - 7505008 RN - 0 (Agglutinins) RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) SB - IM MH - Agglutinins/*analysis/immunology MH - Animals MH - Antibodies, Bacterial/analysis/immunology MH - Brucella Vaccine MH - Brucella abortus/*immunology MH - Brucellosis, Bovine/diagnosis/*immunology/microbiology MH - Cattle MH - Female MH - Male MH - Sex Factors EDAT- 1985/06/01 MHDA- 1985/06/01 00:01 CRDT- 1985/06/01 00:00 PST - ppublish SO - Int J Zoonoses. 1985 Jun;12(2):120-5. PMID- 3937324 OWN - NLM STAT- MEDLINE DA - 19860317 DCOM- 19860317 LR - 20061115 IS - 0165-2427 (Print) IS - 0165-2427 (Linking) VI - 9 IP - 4 DP - 1985 Aug TI - Immune response of cattle to Brucella abortus outer membrane proteins measured by lymphocyte blastogenesis. PG - 383-96 AB - Lymphocytes from cattle were tested in a blastogenesis test with outer membrane proteins isolated from smooth strain 2308 and rough strain 45/20 of Brucella abortus. The titration assay developed for measuring blastogenesis to microbial antigens (Baldwin, Antczak and Winter, this issue, pp. 319-333) was used to assess the response to both group 2 (porins) (Douglas et al., 1984) and group 3 proteins (Verstreate et al., 1982). Blastogenesis was evaluated for distinguishing cattle infected with virulent B. abortus strain 2308 from unimmunized cattle, cattle vaccinated with attenuated strain 19, or inoculated with Escherichia coli 0116:H31, known to cause serological cross-reactions with B. abortus (Nielsen et al., 1980). Strain 45/20 porin was the most effective for this purpose and data analyses utilizing the titration assay were better than those relying on a single point assay. When compared with BASA, an antigen preparation used in other studies (Kaneene et al., 1978a), responses to porin provided a more specific index of infection with B. abortus. Reactions to 45/20 porin occurred, however, in some heifers vaccinated as adults with strain 19 or inoculated with E. coli 0116:H31. Furthermore, nonpregnant heifers had negligible or only transient blastogenesis responses to the porin during the first 14 weeks after infection even though they developed strong 0 antibody responses. We do not recommend the blastogenesis test in its present form as a useful adjunct to serological tests, and could allow measurement of cell mediated immune responses relevant to protective immunity. FAU - Baldwin, C L AU - Baldwin CL FAU - Verstreate, D R AU - Verstreate DR FAU - Winter, A J AU - Winter AJ LA - eng PT - Comparative Study PT - In Vitro PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - NETHERLANDS TA - Vet Immunol Immunopathol JT - Veterinary immunology and immunopathology JID - 8002006 RN - 0 (Antigens, Bacterial) RN - 0 (Bacterial Outer Membrane Proteins) SB - IM MH - Animals MH - Antigens, Bacterial/immunology MH - Bacterial Outer Membrane Proteins/*immunology MH - Brucella abortus/*immunology MH - Brucellosis, Bovine/immunology MH - Cattle/*immunology MH - Escherichia coli/immunology MH - Female MH - *Lymphocyte Activation MH - Species Specificity MH - Vaccination EDAT- 1985/08/01 MHDA- 1985/08/01 00:01 CRDT- 1985/08/01 00:00 PST - ppublish SO - Vet Immunol Immunopathol. 1985 Aug;9(4):383-96. PMID- 6090315 OWN - NLM STAT- MEDLINE DA - 19841106 DCOM- 19841106 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 46 IP - 1 DP - 1984 Oct TI - Ingestion and intracellular survival of Brucella abortus in human and bovine polymorphonuclear leukocytes. PG - 224-30 AB - Bovine polymorphonuclear leukocytes (PMNs) were found to be significantly more bactericidal than human PMNs against a smooth-intermediate strain of Brucella abortus (45/0), whereas there was no difference in bactericidal activity of the two kinds of PMNs against a rough strain of B. abortus (45/20). Electron microscopy of thin sections of PMNs revealed that both strains of B. abortus were readily ingested; however, the extent of degranulation was significantly less than in PMNs incubated with an extracellular parasite, Staphylococcus epidermidis. Amounts of myeloperoxidase and lactoferrin released through exocytosis by PMNs incubated with S. epidermidis were 4.7- and 1.2-fold greater, respectively, than those released from PMNs incubated with B. abortus 45/0. When azurophil and specific granules were isolated after incubation of PMNs with either B. abortus 45/0 or S. epidermidis, results showed that the extent of degranulation by both types of granules was greater in PMNs incubated with S. epidermidis than in those incubated with B. abortus 45/0. Amounts of degranulation by azurophil and specific granules were similar in PMNs incubated with either the smooth-intermediate strain 45/0 or the rough strain 45/20. Degranulation was not stimulated when glutaraldehyde-killed strain 45/0 was substituted for viable cells. These data suggest that B. abortus does not stimulate an effective level of degranulation after ingestion, as observed with extracellular parasites, and that the smooth intermediate strain 45/0 is more resistant to intraleukocytic killing system than the rough strain 45/20. FAU - Riley, L K AU - Riley LK FAU - Robertson, D C AU - Robertson DC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Lactoferrin) RN - EC 1.11.1.7 (Peroxidase) SB - IM MH - Animals MH - Blood Bactericidal Activity MH - Brucella abortus/*growth & development MH - Cattle MH - Exocytosis MH - Humans MH - Intracellular Membranes/physiology MH - Lactoferrin/metabolism MH - Membrane Fusion MH - Microscopy, Electron MH - Neutrophils/*microbiology/parasitology/ultrastructure MH - Peroxidase/metabolism MH - Phagocytosis PMC - PMC261458 OID - NLM: PMC261458 EDAT- 1984/10/01 MHDA- 1984/10/01 00:01 CRDT- 1984/10/01 00:00 PST - ppublish SO - Infect Immun. 1984 Oct;46(1):224-30. PMID- 6440904 OWN - NLM STAT- MEDLINE DA - 19850306 DCOM- 19850306 LR - 20091118 IS - 0095-1137 (Print) IS - 0095-1137 (Linking) VI - 20 IP - 6 DP - 1984 Dec TI - Detection of serum antibody to Brucella abortus in cattle by use of a quantitative fluorometric immunoassay. PG - 1023-7 AB - A quantitative fluorometric immunoassay (FIAX) was adapted for the detection of serum antibodies to Brucella abortus in cattle. Results are expressed in nanograms of immunoglobulin binding the antigen carrier. The FIAX was compared with the standard tube agglutination, Rivanol precipitation, and complement fixation tests, using 285 serum samples from vaccinated, challenged, or control cattle. Linear regression analysis indicated a significant correlation among all four serological tests; the FIAX test correlated best with the Rivanol test. Ninety sera were from vaccinated and nonvaccinated cattle that were challenged with virulent B. abortus 2308. The sensitivity and specificity of each serological test were determined based on culture results from these cattle. The FIAX was the most sensitive of the four serological tests, detecting 79.2% of the culture-positive animals. The FIAX was the least specific, with 15.4% of the culture-negative animals being classified as positive. Eighty-eight sera were from cattle vaccinated with strain 19 but not challenged. All four serological tests had a statistically significant ability to distinguish sera from control and vaccinates on the basis of mean titers. The mean titer of vaccinates was also significantly different from that of challenged animals. Advantages and disadvantages of the FIAX test for bovine brucellosis are discussed. FAU - Hall, S M AU - Hall SM FAU - Confer, A W AU - Confer AW FAU - Tabatabai, L B AU - Tabatabai LB FAU - Deyoe, B L AU - Deyoe BL LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - UNITED STATES TA - J Clin Microbiol JT - Journal of clinical microbiology JID - 7505564 RN - 0 (Antibodies, Bacterial) SB - IM MH - Animals MH - Antibodies, Bacterial/*analysis MH - Brucella abortus/*immunology MH - Brucellosis, Bovine/*diagnosis MH - Cattle MH - *Fluorescent Antibody Technique PMC - PMC271510 OID - NLM: PMC271510 EDAT- 1984/12/01 MHDA- 1984/12/01 00:01 CRDT- 1984/12/01 00:00 PST - ppublish SO - J Clin Microbiol. 1984 Dec;20(6):1023-7. PMID- 6777304 OWN - NLM STAT- MEDLINE DA - 19810219 DCOM- 19810219 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 30 IP - 2 DP - 1980 Nov TI - Comparison of muramyl dipeptide, trehalose dimycolate, and dimethyl dioctadecyl ammonium bromide as adjuvants in Brucella abortus 45/20 vaccines. PG - 409-12 AB - The capacity of trehalose dimycolate (TDM), muramyl dipeptide (MDP), and dimethyl dioctadecyl ammonium bromide (DDA)--alone or in combination--to potentiate the immunogenicity of killed Brucella abortus 45/20 bacteria was studied in guinea pigs. Bacterins that contained TDM in oil droplet emulsion were as effective in the prevention of brucellosis as those emulsified in Freund complete adjuvant, wereas bacterins that contained a combination of TDM and MDP were most effective. Vaccinal emulsions of bacteria and MDP were ineffective in the prevention of splenic infections. Likewise, DDA was unable to potentiate acquired resistance to Brucella. Addition of DDA to 1% oil emulsions of bacteria, TDM, and MDP eliminated protection. Adjuvants without bacteria were not able to nonspecifically protect animals from infection, although TDM was able to significantly reduce the numbers of splenic Brucella. A positive correlation (P < 0.0001) between splenic infection and splenic weight was found. FAU - Woodard, L F AU - Woodard LF FAU - Toone, N M AU - Toone NM FAU - McLaughlin, C A AU - McLaughlin CA LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Cord Factors) RN - 0 (Glycolipids) RN - 0 (Glycopeptides) RN - 0 (Quaternary Ammonium Compounds) RN - 14357-21-2 (dimethyldioctadecylammonium) RN - 53678-77-6 (Acetylmuramyl-Alanyl-Isoglutamine) SB - IM MH - Acetylmuramyl-Alanyl-Isoglutamine/*immunology MH - *Adjuvants, Immunologic MH - Animals MH - Antibodies, Bacterial/biosynthesis MH - Brucella Vaccine/*immunology MH - Brucella abortus/immunology MH - Cord Factors/*immunology MH - Female MH - Glycolipids/*immunology MH - Glycopeptides/*immunology MH - Guinea Pigs MH - Immunity, Innate MH - Quaternary Ammonium Compounds/*immunology MH - Spleen/immunology PMC - PMC551327 OID - NLM: PMC551327 EDAT- 1980/11/01 MHDA- 1980/11/01 00:01 CRDT- 1980/11/01 00:00 PST - ppublish SO - Infect Immun. 1980 Nov;30(2):409-12. PMID- 6810533 OWN - NLM STAT- MEDLINE DA - 19821029 DCOM- 19821029 LR - 20061115 IS - 0378-1135 (Print) IS - 0378-1135 (Linking) VI - 7 IP - 2 DP - 1982 May TI - Serological response of cattle after vaccination and challenge with Brucella abortus. PG - 165-75 AB - New and currently used serological procedures were evaluated using sera from cattle that were challenged with B. abortus S544 (S544) after vaccination with either B. abortus S19 (S19) or B. abortus 45/20 (S45/20) as calves or adults. In animals vaccinated with S19, titres to the indirect haemolysis test (IHLT) rose more slowly, declined more rapidly and involved fewer animals than did titres to the complement fixation test (CFT). In animals vaccinated with S45/20 the rough antigen complement fixation test (RCFT) showed persistent titres. At slaughter the IHLT and CFT were found to be more specific and more sensitive than the Rose Bengal Plate Test (RBPT) and Serum Agglutination Test (SAT) in the detection of cattle infected with B. abortus. FAU - Sutherland, S S AU - Sutherland SS FAU - Le Cras, D V AU - Le Cras DV FAU - Robertson, A G AU - Robertson AG FAU - Johnston, J M AU - Johnston JM FAU - Evans, R J AU - Evans RJ LA - eng PT - Comparative Study PT - Journal Article PL - NETHERLANDS TA - Vet Microbiol JT - Veterinary microbiology JID - 7705469 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) RN - 11121-48-5 (Rose Bengal) SB - IM MH - Agglutination Tests/veterinary MH - Animals MH - Antibodies, Bacterial/*analysis MH - Brucella Vaccine/*immunology MH - Brucella abortus/*immunology MH - Brucellosis, Bovine/diagnosis MH - Cattle/*immunology MH - Complement Fixation Tests/veterinary MH - Coombs' Test/veterinary MH - Female MH - Hemolysis MH - Pregnancy MH - Rose Bengal/diagnostic use MH - Vaccination/*veterinary EDAT- 1982/05/01 MHDA- 1982/05/01 00:01 CRDT- 1982/05/01 00:00 PST - ppublish SO - Vet Microbiol. 1982 May;7(2):165-75. PMID- 6819851 OWN - NLM STAT- MEDLINE DA - 19830421 DCOM- 19830421 LR - 20031114 IS - 0005-0423 (Print) IS - 0005-0423 (Linking) VI - 59 IP - 5 DP - 1982 Nov TI - A study of cattle infected with Brucella abortus and which showed aberrant serological reactions. PG - 132-5 AB - Sixty cows, 48 of which had been vaccinated with live Brucella abortus strain 19 (S19) or with killed B. abortus strain 45/20 (S45/20) and 12 of which were unvaccinated animals, were challenged with B. abortus strain 544. Ten of the 27 cattle found to be infected after challenge showed aberrant serological reactions to the Rose Bengal Plate test, serum agglutination test and/or complement fixation test. These 10 cattle were all previously vaccinated with S19 or S45/20. It was concluded that infection in cattle vaccinated with S19 or S45/20 may be more difficult to detect than infection in animals that have no history of vaccination. FAU - Sutherland, S S AU - Sutherland SS FAU - Le Cras, D V AU - Le Cras DV FAU - Robertson, A G AU - Robertson AG LA - eng PT - Journal Article PL - AUSTRALIA TA - Aust Vet J JT - Australian veterinary journal JID - 0370616 RN - 0 (Antibodies, Bacterial) RN - 11121-48-5 (Rose Bengal) SB - IM MH - Animals MH - Antibodies, Bacterial/analysis MH - Brucella abortus/immunology MH - Brucellosis, Bovine/*immunology MH - Cattle MH - Complement Fixation Tests/veterinary MH - Female MH - Fetal Death/epidemiology/veterinary MH - Hemagglutination Tests/veterinary MH - Pregnancy MH - Pregnancy Complications, Infectious/immunology/*veterinary MH - Rose Bengal/diagnostic use MH - Vaccination/veterinary EDAT- 1982/11/01 MHDA- 1982/11/01 00:01 CRDT- 1982/11/01 00:00 PST - ppublish SO - Aust Vet J. 1982 Nov;59(5):132-5. PMID- 7514802 OWN - NLM STAT- MEDLINE DA - 19940622 DCOM- 19940622 LR - 20061115 IS - 0923-2508 (Print) IS - 0923-2508 (Linking) VI - 144 IP - 6 DP - 1993 Jul-Aug TI - Monoclonal antibodies to Brucella rough lipopolysaccharide: characterization and evaluation of their protective effect against B. abortus. PG - 475-84 AB - We characterized 4 monoclonal antibodies (mAb) specific for rough lipopolysaccharide (R-LPS) of Brucella. mAb were selected by enzyme-linked immunosorbent assay (ELISA) on whole B. abortus 45/20 rough cells and R-LPS from B. melitensis B115 rough cells. Specificity was confirmed by immunoblot analysis using R-LPS and smooth LPS (S-LPS) preparations. Anti-R-LPS revealed the low molecular mass R-LPS molecules below 20.1 kDa in the R-LPS and S-LPS preparations as well as the typical A and M patterns in high molecular mass S-LPS molecules (between 21.5 and 66 kDa) in the S-LPS preparations. An O-polysaccharide-specific mAb revealed only high molecular mass S-LPS molecules in the S-LPS preparation. In ELISA the anti-R-LPS mAb bound better on rough than on smooth B. abortus 544 whole cells, and this was confirmed by immunoelectron microscopy. Protective activity of anti-R-LPS mAb of different isotypes was tested on mice and compared with an S-LPS-specific mAb. Only the IgG3 mAb reduced significantly the splenic infection but did not reach the level of protection conferred by the S-LPS-specific mAb. AD - Institut National de la Recherche Agronomique, Centre de Recherches de Tours, Nouzilly, France. FAU - Cloeckaert, A AU - Cloeckaert A FAU - Jacques, I AU - Jacques I FAU - Bowden, R A AU - Bowden RA FAU - Dubray, G AU - Dubray G FAU - Limet, J N AU - Limet JN LA - eng PT - In Vitro PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - FRANCE TA - Res Microbiol JT - Research in microbiology JID - 8907468 RN - 0 (Antibodies, Monoclonal) RN - 0 (Epitopes) RN - 0 (Lipopolysaccharides) SB - IM MH - Animals MH - Antibodies, Monoclonal/immunology/*isolation & purification MH - Brucella abortus/*immunology/ultrastructure MH - Brucella melitensis/*immunology MH - Enzyme-Linked Immunosorbent Assay MH - Epitopes/immunology MH - Immunoblotting MH - Immunohistochemistry MH - Lipopolysaccharides/*immunology MH - Mice MH - Microscopy, Electron MH - Splenic Diseases/immunology/microbiology EDAT- 1993/07/01 MHDA- 1993/07/01 00:01 CRDT- 1993/07/01 00:00 AID - 0923-2508(93)90055-7 [pii] PST - ppublish SO - Res Microbiol. 1993 Jul-Aug;144(6):475-84. PMID- 7619903 OWN - NLM STAT- MEDLINE DA - 19950831 DCOM- 19950831 LR - 20071115 IS - 1040-6387 (Print) IS - 1040-6387 (Linking) VI - 7 IP - 2 DP - 1995 Apr TI - Evaluation of an enzyme-linked immunosorbent assay for the detection of sheep infected and vaccinated with Brucella melitensis. PG - 206-9 AB - An indirect enzyme-linked immunosorbent assay (ELISA), using the lipopolysaccharide of the cell wall as an antigen, was used to detect Brucella melitensis antibodies in ovine serum. The test was carried out on 703 samples of field serums, which were also analyzed by the complement fixation (CF) test and the rose Bengal (RB) test. The ELISA results were more similar to those of the CF test (kappa = 0.89) than to the results of the RB test (kappa = 0.73). The ELISA also had high sensitivity (94.7%) and a somewhat lower specificity (90.4%). One group of 139 young brucellosis-free animals 3-6 months of age were vaccinated with B. melitensis rev. 1 at a dose of 1.2 x 10(9) live organisms. The ELISA detected a significantly lower number of reactors than the CF and RB tests (P < 0.001). The ELISA values remained below the cutoff level during the 9 months following vaccination. AD - Departamento de Sanidad Animal (Enfermedades Infecciosas y Epidemiologia), Facultad de Veterinaria, Universidad de Leon, Spain. FAU - Delgado, S AU - Delgado S FAU - Fernandez, M AU - Fernandez M FAU - Carmenes, P AU - Carmenes P LA - eng PT - Comparative Study PT - Journal Article PL - UNITED STATES TA - J Vet Diagn Invest JT - Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc JID - 9011490 RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 0 (Lipopolysaccharides) RN - 11121-48-5 (Rose Bengal) SB - IM MH - Animals MH - Antibodies, Bacterial/*blood MH - Antigens, Bacterial MH - Brucella melitensis/*immunology MH - Brucellosis/diagnosis/prevention & control/*veterinary MH - Complement Fixation Tests/methods/statistics & numerical data/veterinary MH - Enzyme-Linked Immunosorbent Assay/methods/statistics & numerical data/*veterinary MH - Evaluation Studies as Topic MH - Female MH - Lipopolysaccharides/immunology MH - Rose Bengal MH - Sensitivity and Specificity MH - Sheep MH - Sheep Diseases/*diagnosis/immunology/prevention & control MH - Vaccination/veterinary EDAT- 1995/04/01 MHDA- 1995/04/01 00:01 CRDT- 1995/04/01 00:00 PST - ppublish SO - J Vet Diagn Invest. 1995 Apr;7(2):206-9. PMID- 8711894 OWN - NLM STAT- MEDLINE DA - 19960909 DCOM- 19960909 LR - 20061115 IS - 0165-7380 (Print) IS - 0165-7380 (Linking) VI - 20 IP - 2 DP - 1996 TI - A comparison of the potency of several Brucella allergens used to detect brucellosis in cattle. PG - 141-51 AB - The potency of Brucella allergens prepared from a smooth Brucella abortus strain S-99, mucoid strain Leewarden, rough strain 45/20, and rough Brucella melitensis strain B-115 was assessed. The potency of these allergens was compared with that of a standard allergen prepared from smooth Brucella abortus S-99 that efficiently detected bovine brucellosis in other studies. Eight cattle experimentally inoculated with Brucella abortus 544 were tested with the allergens 4 and 10 weeks after infection, and again 8 months after infection. All the allergens effectively detected infection but there was a clear distinction in the mean skin reactions 48 and 72 h after injection of the allergens. The skin reactions provoked by the allergens prepared from smooth or mucoid strains of Brucella were most pronounced 48 h after injection. Skin reactions provoked by allergens prepared from rough strains of Brucella were strongest 72 h after injection. Allergens prepared from smooth or mucoid Brucella strains were more potent in detecting brucellosis than those prepared from rough strains of Brucella. AD - Department of Bacteriology, Institute for Animal Science and Health (ID-DLO), Lelystad, The Netherlands. FAU - Bercovich, Z AU - Bercovich Z FAU - Dekker, T AU - Dekker T FAU - Eger, A AU - Eger A FAU - Haagsma, J AU - Haagsma J LA - eng PT - Comparative Study PT - Journal Article PL - NETHERLANDS TA - Vet Res Commun JT - Veterinary research communications JID - 8100520 RN - 0 (Allergens) RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) SB - IM MH - Acute Disease MH - Allergens/*diagnostic use/immunology MH - Animals MH - Antibodies, Bacterial/blood/immunology MH - Antigens, Bacterial/diagnostic use/immunology MH - Brucella abortus/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis, Bovine/*diagnosis/*immunology/pathology MH - Cattle MH - Chronic Disease MH - Hypersensitivity, Delayed/immunology/pathology/veterinary MH - Skin/immunology/pathology/physiopathology MH - Skin Tests/standards/veterinary EDAT- 1996/01/01 MHDA- 1996/01/01 00:01 CRDT- 1996/01/01 00:00 PST - ppublish SO - Vet Res Commun. 1996;20(2):141-51. PMID- 8926120 OWN - NLM STAT- MEDLINE DA - 19961114 DCOM- 19961114 LR - 20091119 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 64 IP - 10 DP - 1996 Oct TI - Immunological response to the Brucella abortus GroEL homolog. PG - 4396-400 AB - Western blot (immunoblot) analysis of sera from cattle vaccinated with Brucella abortus S19 exhibit an elevated serologic response to Hsp62, the GroEL homolog (BaGroEL). Serologic screening of individual cows vaccinated with B. abortus S19 revealed no correlation between the immune response to BaGroEL and protection against a challenge with virulent organisms. The humoral immune response to BaGroEL was restricted to a region of the mature protein which mapped to amino acids 317 to 355 and may represent a useful diagnostic tool for monitoring exposure to B. abortus. Immunity to a challenge with virulent B. abortus S2308 was not observed in the BaGroEL vaccinated mouse model. AD - Department of Veterinary Pathology, College of Veterinary Medicine, Texas A&M University, College Station 77843-4467, USA. FAU - Lin, J AU - Lin J FAU - Adams, L G AU - Adams LG FAU - Ficht, T A AU - Ficht TA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Chaperonin 60) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Blotting, Western MH - Brucella abortus/*immunology MH - Cattle MH - Chaperonin 60/*immunology MH - Female MH - Mice MH - Rabbits MH - Vaccination PMC - PMC174388 OID - NLM: PMC174388 EDAT- 1996/10/01 MHDA- 1996/10/01 00:01 CRDT- 1996/10/01 00:00 PST - ppublish SO - Infect Immun. 1996 Oct;64(10):4396-400. PMID- 8945575 OWN - NLM STAT- MEDLINE DA - 19970108 DCOM- 19970108 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 64 IP - 12 DP - 1996 Dec TI - Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models. PG - 5263-8 AB - A mucosal vaccine against brucellosis consisting of the lipopolysaccharide (LPS) of Brucella melitensis complexed with the outer membrane protein (GBOMP) of group B Neisseria meningitidis was tested in small-animal models of intranasal immunization. Mice given two doses of the vaccine developed high levels of immunoglobulin G (IgG) and IgA antibodies specific for B. melitensis LPS in lung lavages and specific IgG and IgA antibody-secreting cells in the lungs and spleen. Similarly, in guinea pigs immunized twice intranasally, IgG and IgA LPS-specific antibodies were detected in lung lavages, and specific antibody-secreting cells were isolated from the spleen and cervical nodes. In mice immunized with LPS only, pulmonary responses consisted mostly of IgM antibodies, while guinea pigs given LPS alone developed local antibody of all three isotypes, but at lower levels compared to animals given the complex vaccine. Both mice and guinea pigs also developed high levels of serum IgG and moderate levels of IgA as a result of intranasal immunization with the complex vaccine. The serum antibodies in both cases were found to cross-react with the LPS of B. abortus, which shares an immunogenic epitope with B. melitensis LPS. In mice given the complex vaccine, there was a prominent serum IgG1 response that was absent in the mice given LPS alone. In conclusion, the N. meningitidis GBOMP was an effective mucosal adjuvant for secretory IgA and IgG responses in the lungs of both mice and guinea pigs. The IgG1 subclass response in mice suggests that GBOMP may have favored a Th2 type of response to the LPS. A vaccine capable of stimulating high levels of antibody at local sites has the potential to protect against brucellae, since these pathogens gain entry to the host via mucosal routes. AD - Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, D.C. 20307, USA. FAU - Van De Verg, L L AU - Van De Verg LL FAU - Hartman, A B AU - Hartman AB FAU - Bhattacharjee, A K AU - Bhattacharjee AK FAU - Tall, B D AU - Tall BD FAU - Yuan, L AU - Yuan L FAU - Sasala, K AU - Sasala K FAU - Hadfield, T L AU - Hadfield TL FAU - Zollinger, W D AU - Zollinger WD FAU - Hoover, D L AU - Hoover DL FAU - Warren, R L AU - Warren RL LA - eng PT - Journal Article PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Adjuvants, Immunologic) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Lipopolysaccharides) SB - IM MH - *Adjuvants, Immunologic MH - Administration, Intranasal MH - Animals MH - Bacterial Outer Membrane Proteins/*immunology MH - Brucella melitensis/*immunology MH - Guinea Pigs MH - *Immunization MH - Lipopolysaccharides/*immunology MH - Mice MH - Neisseria meningitidis/*immunology PMC - PMC174517 OID - NLM: PMC174517 EDAT- 1996/12/01 MHDA- 1996/12/01 00:01 CRDT- 1996/12/01 00:00 PST - ppublish SO - Infect Immun. 1996 Dec;64(12):5263-8. PMID- 10921983 OWN - NLM STAT- MEDLINE DA - 20000920 DCOM- 20000920 LR - 20091118 IS - 0095-1137 (Print) IS - 0095-1137 (Linking) VI - 38 IP - 8 DP - 2000 Aug TI - Validation of the abbreviated Brucella AMOS PCR as a rapid screening method for differentiation of Brucella abortus field strain isolates and the vaccine strains, 19 and RB51. PG - 3085-6 AB - The Brucella AMOS PCR assay was previously developed to identify and differentiate specific Brucella species. In this study, an abbreviated Brucella AMOS PCR test was evaluated to determine its accuracy in differentiating Brucella abortus into three categories: field strains, vaccine strain 19 (S19), and vaccine strain RB51/parent strain 2308 (S2308). Two hundred thirty-one isolates were identified and tested by the conventional biochemical tests and Brucella AMOS PCR. This included 120 isolates identified as B. abortus S19, 9 identified as B. abortus strain RB51, 57 identified as B. abortus biovar 1, 15 identified as B. abortus bv. 2, 1 identified as B. abortus bv. 2 (M antigen dominant), 7 identified as B. abortus bv. 4, and 22 identified as B. abortus S2308 and isolated from experimentally infected cattle. The Brucella AMOS PCR correctly identified each isolate as RB51/S2308, S19, or a field strain of Brucella. AD - National Veterinary Services Laboratories, Veterinary Services, Animal and Plant Health and Inspection Service, U.S. Department of Agriculture, Ames, Iowa 50010, USA. Darla.R.Ewalt@usda.gov FAU - Ewalt, D R AU - Ewalt DR FAU - Bricker, B J AU - Bricker BJ LA - eng PT - Journal Article PL - UNITED STATES TA - J Clin Microbiol JT - Journal of clinical microbiology JID - 7505564 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Brucella Vaccine MH - Brucella abortus/*classification/*genetics/immunology MH - Brucellosis, Bovine/*microbiology MH - Cattle MH - Mass Screening MH - Polymerase Chain Reaction/*methods MH - Reproducibility of Results PMC - PMC87192 OID - NLM: PMC87192 EDAT- 2000/08/02 11:00 MHDA- 2000/09/23 11:01 CRDT- 2000/08/02 11:00 PST - ppublish SO - J Clin Microbiol. 2000 Aug;38(8):3085-6. PMID- 11401980 OWN - NLM STAT- MEDLINE DA - 20010612 DCOM- 20010719 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 69 IP - 7 DP - 2001 Jul TI - Deletion of wboA enhances activation of the lectin pathway of complement in Brucella abortus and Brucella melitensis. PG - 4407-16 AB - Brucella spp. are gram-negative intracellular pathogens that survive and multiply within phagocytic cells of their hosts. Smooth organisms present O polysaccharides (OPS) on their surface. These OPS help the bacteria avoid the bactericidal action of serum. The wboA gene, coding for the enzyme glycosyltransferase, is essential for the synthesis of O chain in Brucella. In this study, the sensitivity to serum of smooth, virulent Brucella melitensis 16M and B. abortus 2308, rough wboA mutants VTRM1, RA1, and WRR51 derived from these two Brucella species, and the B. abortus vaccine strain RB51 was assayed using normal nonimmune human serum (NHS). The deposition of complement components and mannose-binding lectin (MBL) on the bacterial surface was detected by flow cytometry. Rough B. abortus mutants were more sensitive to the bactericidal action of NHS than were rough B. melitensis mutants. Complement components were deposited on smooth strains at a slower rate compared to rough strains. Deposition of iC3b and C5b-9 and bacterial killing occurred when bacteria were treated with C1q-depleted, but not with C2-depleted serum or NHS in the presence of Mg-EGTA. These results indicate that (i) OPS-deficient strains derived from B. melitensis 16M are more resistant to the bactericidal action of NHS than OPS-deficient strains derived from B. abortus 2308, (ii) both the classical and the MBL-mediated pathways are involved in complement deposition and complement-mediated killing of Brucella, and (iii) the alternative pathway is not activated by smooth or rough brucellae. AD - Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, DC, 20307, USA. Carmen.Fernandez-Prada@NA.AMEDD.ARMY.MIL FAU - Fernandez-Prada, C M AU - Fernandez-Prada CM FAU - Nikolich, M AU - Nikolich M FAU - Vemulapalli, R AU - Vemulapalli R FAU - Sriranganathan, N AU - Sriranganathan N FAU - Boyle, S M AU - Boyle SM FAU - Schurig, G G AU - Schurig GG FAU - Hadfield, T L AU - Hadfield TL FAU - Hoover, D L AU - Hoover DL LA - eng PT - Journal Article PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Carrier Proteins) RN - 0 (Collectins) RN - 0 (Lectins) RN - EC 2.4.- (Glycosyltransferases) SB - IM MH - Brucella abortus/*metabolism MH - Brucella melitensis/*metabolism MH - Carrier Proteins/*metabolism MH - Collectins MH - Glycosyltransferases/genetics/*metabolism MH - Humans MH - Lectins/*metabolism PMC - PMC98513 OID - NLM: PMC98513 EDAT- 2001/06/13 10:00 MHDA- 2001/07/20 10:01 CRDT- 2001/06/13 10:00 AID - 10.1128/IAI.69.7.4407-4416.2001 [doi] PST - ppublish SO - Infect Immun. 2001 Jul;69(7):4407-16. PMID- 12414166 OWN - NLM STAT- MEDLINE DA - 20021104 DCOM- 20030303 LR - 20041117 IS - 0378-1135 (Print) IS - 0378-1135 (Linking) VI - 90 IP - 1-4 DP - 2002 Dec 20 TI - Brucellosis vaccines: past, present and future. PG - 479-96 AB - The first effective Brucella vaccine was based on live Brucella abortus strain 19, a laboratory-derived strain attenuated by an unknown process during subculture. This induces reasonable protection against B. abortus, but at the expense of persistent serological responses. A similar problem occurs with the B. melitensis Rev.1 strain that is still the most effective vaccine against caprine and ovine brucellosis. Vaccines based on killed cells of virulent strains administered with adjuvant induced significant protection but also unacceptable levels of antibodies interfering with diagnostic tests. Attempts were made to circumvent this problem by using a live rough strain B. abortus 45/20, but this reverted to virulence in vivo. Use of killed cells of this strain in adjuvant met with moderate success but batch to batch variation in reactogenicity and agglutinogenicity limited application. This problem has been overcome by the development of the rifampicin-resistant mutant B. abortus RB51 strain. This strain has proved safe and effective in the field against bovine brucellosis and exhibits negligible interference with diagnostic serology. Attempts are being made to develop defined rough mutant vaccine strains that would be more effective against B. melitensis and B. suis. Various studies have examined cell-free native and recombinant proteins as candidate protective antigens, with or without adjuvants. Limited success has been obtained with these or with DNA vaccines encoding known protective antigens in experimental models and further work is indicated. CI - Copyright 2002 Elsevier Science B.V. AD - Center for Molecular Medicine and Infectious Diseases, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA. FAU - Schurig, Gerhardt G AU - Schurig GG FAU - Sriranganathan, Nammalwar AU - Sriranganathan N FAU - Corbel, Michael J AU - Corbel MJ LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Vet Microbiol JT - Veterinary microbiology JID - 7705469 RN - 0 (Bacterial Vaccines) RN - 0 (Vaccines, Attenuated) RN - 0 (Vaccines, DNA) SB - IM MH - Animals MH - Animals, Domestic MH - Animals, Wild MH - *Bacterial Vaccines MH - Brucella abortus/*immunology MH - Brucella melitensis/immunology MH - Brucellosis, Bovine/*immunology MH - Cattle MH - Vaccination/*methods/trends/veterinary MH - Vaccines, Attenuated MH - Vaccines, DNA RF - 121 EDAT- 2002/11/05 04:00 MHDA- 2003/03/04 04:00 CRDT- 2002/11/05 04:00 AID - S0378113502002559 [pii] PST - ppublish SO - Vet Microbiol. 2002 Dec 20;90(1-4):479-96. PMID- 12414168 OWN - NLM STAT- MEDLINE DA - 20021104 DCOM- 20030303 LR - 20031114 IS - 0378-1135 (Print) IS - 0378-1135 (Linking) VI - 90 IP - 1-4 DP - 2002 Dec 20 TI - Brucella abortus RB51: enhancing vaccine efficacy and developing multivalent vaccines. PG - 521-32 AB - Brucella abortus vaccine strain RB51 is an attenuated, stable rough mutant that is being used in many countries to control bovine brucellosis. Our earlier study demonstrated that the protective efficacy of strain RB51 can be significantly enhanced by overexpressing Cu-Zn superoxide dismutase (SOD), a homologous protective antigen. We have also previously demonstrated that strain RB51 can be engineered to express heterologous proteins and mice vaccinated with such recombinant RB51 strains develop a strong Th1 type of immune response to the foreign proteins. The present study is aimed at combining these two characteristics to generate new recombinant RB51 vaccines with enhanced abilities to protect against brucellosis and simultaneously able to protect against infections by Mycobacterium spp. We constructed two recombinant RB51 strains, RB51SOD/85A which overexpresses SOD with simultaneous expression of the 85A, a protective protein of Mycobacterium spp., and RB51ESAT which expresses ESAT-6, another protective protein of M. bovis, as a fusion protein with the signal sequence and few additional amino terminal amino acids of SOD. Mice vaccinated with these recombinant strains developed specific immune responses to the mycobacterial proteins and significantly enhanced protection against Brucella challenge compared to the mice vaccinated with strain RB51 alone. CI - Copyright 2002 Elsevier Science B.V. AD - Department of Veterinary Pathobiology, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907-1243, USA. rvemulap@purdue.edu FAU - Vemulapalli, Ramesh AU - Vemulapalli R FAU - He, Yongqun AU - He Y FAU - Sriranganathan, Nammalwar AU - Sriranganathan N FAU - Boyle, Stephen M AU - Boyle SM FAU - Schurig, Gerhardt G AU - Schurig GG LA - eng PT - Journal Article PL - Netherlands TA - Vet Microbiol JT - Veterinary microbiology JID - 7705469 RN - 0 (Bacterial Vaccines) RN - 0 (DNA Primers) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - *Bacterial Vaccines/immunology MH - Base Sequence MH - Brucella abortus/genetics/*immunology MH - Brucellosis, Bovine/*immunology/prevention & control MH - Cattle MH - Cloning, Molecular MH - DNA Primers MH - Mycobacterium/genetics MH - Mycobacterium bovis/immunology MH - Polymerase Chain Reaction MH - Recombination, Genetic MH - Superoxide Dismutase/genetics EDAT- 2002/11/05 04:00 MHDA- 2003/03/04 04:00 CRDT- 2002/11/05 04:00 AID - S0378113502002328 [pii] PST - ppublish SO - Vet Microbiol. 2002 Dec 20;90(1-4):521-32. PMID- 12528440 OWN - NLM STAT- MEDLINE DA - 20030116 DCOM- 20030626 LR - 20061115 IS - 0090-3558 (Print) IS - 0090-3558 (Linking) VI - 38 IP - 4 DP - 2002 Oct TI - Immune responses of bison to ballistic or hand vaccination with Brucella abortus strain RB51. PG - 738-45 AB - From January through July of 2000, a study was conducted to evaluate clearance, immunologic responses, and potential shedding of Brucella abortus strain RB51 (SRB51) following ballistic or subcutaneous (SQ) vaccination of 7 mo old bison (Bison bison) calves. Ten bison calves were vaccinated SQ with 1.4 x 10(10) colony-forming units (CFU) of SRB51 and five calves were inoculated SQ with sterile 0.15 M sodium chloride. An additional 10 bison calves were ballistically inoculated in the rear leg musculature with 1 x 10(10) CFU of SRB51 and five calves were ballistically inoculated with an empty Biobullet. Serologic responses were monitored at 0, 2, 4, 6, 8, 12, 18, and 24 wk using the standard tube agglutination test and a dot-blot assay. Swabs from rectal, vaginal, nasal, and ocular mucosal surfaces, and blood were obtained for culture from all bison at 2, 4, 6, and 8 weeks post-inoculation to evaluate potential shedding by vaccinated bison or persistent septicemia. The superficial cervical lymph node was biopsied in eight ballistic and eight hand vaccinated bison at 6 or 12 wk to evaluate clearance of the vaccine strain from lymphatic tissues. Lymphocyte proliferative responses to irradiated SRB51 bacteria were evaluated in peripheral blood mononuclear cells (PBMC) at 4, 6, 8, 12, 18, and 24 wk after inoculation. Serum obtained from hand or ballistically vaccinated bison demonstrated antibody responses on the dot-blot assay that were greater than control bison (saline or empty Biobullet) at 2, 4, 6, and 8 wk after vaccination. Antibody titers of ballistically vaccinated bison did not differ (P > 0.05) from hand vaccinated bison at any sampling time. Blood samples obtained from all bison at 2, 4, 6 and 8 wk after vaccination were negative for SRB51. One colony of SRB51 was recovered from the vaginal swab of one ballistically vaccinated bison at 2 wk after vaccination. All other ocular, vaginal, nasal, and rectal swabs were culture negative for SRB51. Strain RB51 was recovered from superficial cervical lymph nodes of hand and ballistic vaccinated bison at 6 (two of four and two of four bison, respectively) and 12 wk (three of four and one of four bison, respectively). Serologic tests and bacterial culture techniques failed to demonstrate infection of nonvaccinated bison. Peripheral blood mononuclear cells obtained from hand vaccinated bison had greater (P < 0.05) proliferative responses to strain RB51 bacteria when compared to PBMC from nonvaccinated and ballistically vaccinated bison. Proliferative responses of PBMC from ballistically vaccinated bison did not differ (P > 0.05) at any sampling time from proliferative responses of PBMC from control bison. Serum alpha 1-acid glycoprotein concentrations, plasma fibrinogen, and total protein concentrations were not influenced by treatments. Ballistic delivery of SRB51 did not induce adverse effects or influence clearance of the vaccine strain. There were no proliferative responses of PBMC to SRB51 in bison ballistically vaccinated with SRB51; whereas bison inoculated with SRB51 by hand injection had greater proliferative responses than control or ballistically vaccinated bison. Our study suggests that ballistic delivery may require a greater dose of SRB51 to induce cell-mediated immune responses in bison that are comparable to those induced by hand injection, and that ballistic or hand delivery of 1 x 10(10) CFU of SRB51 is safe in bison calves. AD - Bacterial Diseases Research Unit, National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, Iowa 50010, USA. Solsen@nadc.ars.usda.gov FAU - Olsen, Steven C AU - Olsen SC FAU - Kreeger, Terry J AU - Kreeger TJ FAU - Schultz, Will AU - Schultz W LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - J Wildl Dis JT - Journal of wildlife diseases JID - 0244160 RN - 0 (Antibodies, Bacterial) RN - 0 (Blood Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Orosomucoid) RN - 9001-32-5 (Fibrinogen) SB - IM MH - Animals MH - Antibodies, Bacterial/*biosynthesis/blood MH - *Bison MH - Blood Proteins/analysis MH - Brucella Vaccine/*administration & dosage MH - Brucella abortus/*immunology MH - Female MH - Fibrinogen/analysis MH - Lymph Nodes/pathology MH - Lymphocyte Activation MH - Orosomucoid/analysis MH - Vaccination/methods/*veterinary EDAT- 2003/01/17 04:00 MHDA- 2003/06/27 05:00 CRDT- 2003/01/17 04:00 PST - ppublish SO - J Wildl Dis. 2002 Oct;38(4):738-45. PMID- 12853399 OWN - NLM STAT- MEDLINE DA - 20030710 DCOM- 20040430 LR - 20091118 IS - 1071-412X (Print) IS - 1071-412X (Linking) VI - 10 IP - 4 DP - 2003 Jul TI - Epitope mapping of the Brucella melitensis BP26 immunogenic protein: usefulness for diagnosis of sheep brucellosis. PG - 647-51 AB - Sequencing of bp26, the gene encoding the Brucella sp. immunogenic BP26 periplasmic protein, was performed in the reference strains of Brucella abortus, B. suis, and B. ovis. The three bp26 sequences were almost identical to that published for B. melitensis 16M bp26, and only minor nucleotide substitutions, without modifying the amino acid sequence, were observed between species. The bp26 genes of the seven B. abortus biovar reference strains and B. abortus S19 and RB51 vaccine strains were also sequenced. Again, only minor differences were found. Surprisingly, the bp26 nucleotide sequence for B. abortus S19 was almost identical to that found for B. melitensis 16M and differed from the sequence described previously by others (O. L. Rossetti, A. I. Arese, M. L. Boschiroli, and S. L. Cravero, J. Clin. Microbiol. 34:165-169, 1996) for the same B. abortus strain. The epitope mapping of BP26, performed by using a panel of monoclonal antibodies and recombinant DNA techniques, allowed the identification of an immunodominant region of the protein interesting for the diagnosis of B. melitensis and B. ovis infection in sheep. A recombinant fusion protein containing this region of BP26 reacted indeed, in Western blotting, as the entire recombinant BP26 against sera from B. melitensis- or B. ovis-infected sheep while it avoided false-positive reactions observed with sera from Brucella-free sheep when using the entire recombinant BP26. Thus, use of this recombinant fusion protein instead the entire recombinant BP26 could improve the specific serological diagnosis of B. melitensis or B. ovis infection in sheep. AD - Departamento de Microbiologia y Genetica, Universidad de Salamanca, 37007 Salamanca, Spain. FAU - Seco-Mediavilla, Patricia AU - Seco-Mediavilla P FAU - Verger, Jean-Michel AU - Verger JM FAU - Grayon, Maggy AU - Grayon M FAU - Cloeckaert, Axel AU - Cloeckaert A FAU - Marin, Clara M AU - Marin CM FAU - Zygmunt, Michel S AU - Zygmunt MS FAU - Fernandez-Lago, Luis AU - Fernandez-Lago L FAU - Vizcaino, Nieves AU - Vizcaino N LA - eng PT - Comparative Study PT - Evaluation Studies PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Diagn Lab Immunol JT - Clinical and diagnostic laboratory immunology JID - 9421292 RN - 0 (Antigens, Bacterial) RN - 0 (BP26 protein, Brucella) RN - 0 (Bacterial Proteins) RN - 0 (Immunodominant Epitopes) RN - 0 (Membrane Proteins) RN - 0 (Recombinant Fusion Proteins) SB - IM MH - Amino Acid Sequence MH - Animals MH - Antigens, Bacterial/genetics/*immunology MH - Bacterial Proteins/genetics/*immunology MH - Brucella melitensis/genetics/*immunology MH - Brucella ovis/immunology MH - Brucella suis/immunology MH - Brucellosis/diagnosis/microbiology/*veterinary MH - *Epitope Mapping MH - Genes, Bacterial MH - Immunodominant Epitopes/genetics/*immunology MH - Membrane Proteins/genetics/*immunology MH - Molecular Sequence Data MH - Recombinant Fusion Proteins/immunology MH - Sequence Alignment MH - Sequence Homology, Amino Acid MH - Sheep MH - Sheep Diseases/*diagnosis/microbiology MH - Species Specificity PMC - PMC164270 OID - NLM: PMC164270 EDAT- 2003/07/11 05:00 MHDA- 2004/05/01 05:00 CRDT- 2003/07/11 05:00 PST - ppublish SO - Clin Diagn Lab Immunol. 2003 Jul;10(4):647-51. PMID- 12933826 OWN - NLM STAT- MEDLINE DA - 20030822 DCOM- 20030929 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 71 IP - 9 DP - 2003 Sep TI - A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. PG - 4857-61 AB - This study was conducted to evaluate the immunogenicity and protective efficacy of a DNA vaccine encoding Brucella abortus Cu,Zn superoxide dismutase (SOD). Intramuscular injection of plasmid DNA carrying the SOD gene (pcDNA-SOD) into BALB/c mice elicited both humoral and cellular immune responses. Animals injected with pcDNA-SOD developed SOD-specific antibodies which exhibited a dominance of immunoglobulin G2a (IgG2a) over IgG1. In addition, the DNA vaccine elicited a T-cell-proliferative response and also induced the production of gamma interferon, but not interleukin-10 (IL-10) or IL-4, upon restimulation with either recombinant SOD or crude Brucella protein, suggesting the induction of a typical T-helper-1-dominated immune response in mice. The pcDNA-SOD (but not the control vector) induced a strong, significant level of protection in BALB/c mice against challenge with B. abortus virulent strain 2308; the level of protection was similar to the one induced by B. abortus vaccine strain RB51. Altogether, these data suggest that pcDNA-SOD is a good candidate for use in future studies of vaccination against brucellosis. AD - Molecular Immunology Laboratory, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepcion, Concepcion, Chile. aonate@udec.cl FAU - Onate, Angel A AU - Onate AA FAU - Cespedes, Sandra AU - Cespedes S FAU - Cabrera, Alex AU - Cabrera A FAU - Rivers, Rodolfo AU - Rivers R FAU - Gonzalez, Andres AU - Gonzalez A FAU - Munoz, Carola AU - Munoz C FAU - Folch, Hugo AU - Folch H FAU - Andrews, Edilia AU - Andrews E LA - eng PT - In Vitro PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Vaccines) RN - 0 (DNA, Bacterial) RN - 0 (Vaccines, DNA) RN - 82115-62-6 (Interferon-gamma) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - Antibodies, Bacterial/biosynthesis MH - Bacterial Vaccines/*genetics/*pharmacology MH - Brucella abortus/*enzymology/genetics/*immunology MH - Brucellosis/immunology/prevention & control MH - DNA, Bacterial/genetics MH - Female MH - Interferon-gamma/biosynthesis MH - Lymphocyte Activation MH - Mice MH - Mice, Inbred BALB C MH - Superoxide Dismutase/*genetics/*immunology MH - Th1 Cells/immunology MH - Vaccines, DNA/*genetics/*pharmacology PMC - PMC187304 OID - NLM: PMC187304 EDAT- 2003/08/23 05:00 MHDA- 2003/09/30 05:00 CRDT- 2003/08/23 05:00 PST - ppublish SO - Infect Immun. 2003 Sep;71(9):4857-61. PMID- 12933870 OWN - NLM STAT- MEDLINE DA - 20030822 DCOM- 20030929 LR - 20091118 IS - 0019-9567 (Print) IS - 0019-9567 (Linking) VI - 71 IP - 9 DP - 2003 Sep TI - Purification and characterization of an immunogenic aminopeptidase of Brucella melitensis. PG - 5238-44 AB - An immunogenic aminopeptidase was purified from Brucella melitensis strain VTRM1. The purification procedure consisted of ammonium sulfate fractionation and three chromatographic steps. This procedure resulted in a yield of 29% and a 144-fold increase in specific activity. The aminopeptidase appeared to be a monomeric enzyme with a molecular mass of 96 kDa and an isoelectric point of 4.8. Its activity was optimal at pH 7.0 at 40 degrees C. The enzyme was strongly inhibited by EDTA, 1,10-phenathroline, and divalent cations (Zn(2+) and Hg(2+)), suggesting that this protein was a metalloaminopeptidase. The enzyme showed preference for alanine at the N termini of aminoacyl derivatives. The K(m) values for L-alanine-p-nitroanilide (Ala-pNA) and Lys-pNA were 0.35 and 0.18 mM, respectively. The N-terminal sequence of aminopeptidase was used for a homologous search in the genomes of B. melitensis 16M and Brucella suis 1330. The analysis revealed an exact match of the probe sequence (36 bp) with an open reading frame of 2,652 bp encoding a protein predicted to be alanyl aminopeptidase (aminopeptidase N). Collectively, these data suggest designation of the B. melitensis enzyme as an aminopeptidase N. The aminopeptidase was recognized by sera from patients with acute and chronic brucellosis, suggesting that the enzyme may have important diagnostic implications. AD - Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico. FAU - Contreras-Rodriguez, Araceli AU - Contreras-Rodriguez A FAU - Ramirez-Zavala, Bernardo AU - Ramirez-Zavala B FAU - Contreras, Andrea AU - Contreras A FAU - Schurig, Gerhardt G AU - Schurig GG FAU - Sriranganathan, Nammalwar AU - Sriranganathan N FAU - Lopez-Merino, Ahide AU - Lopez-Merino A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Antibodies, Bacterial) RN - 0 (Protease Inhibitors) RN - EC 3.4.11.- (Aminopeptidases) SB - IM MH - Amino Acid Sequence MH - Aminopeptidases/genetics/*immunology/*isolation & purification/metabolism MH - Antibodies, Bacterial/blood MH - Brucella melitensis/*enzymology/genetics/*immunology MH - Brucellosis/diagnosis/immunology MH - Humans MH - Hydrogen-Ion Concentration MH - Isoelectric Point MH - Kinetics MH - Molecular Weight MH - Protease Inhibitors/pharmacology MH - Substrate Specificity MH - Temperature PMC - PMC187343 OID - NLM: PMC187343 EDAT- 2003/08/23 05:00 MHDA- 2003/09/30 05:00 CRDT- 2003/08/23 05:00 PST - ppublish SO - Infect Immun. 2003 Sep;71(9):5238-44. PMID- 15099501 OWN - NLM STAT- MEDLINE DA - 20040421 DCOM- 20040930 LR - 20061115 IS - 0928-4249 (Print) IS - 0928-4249 (Linking) VI - 35 IP - 1 DP - 2004 Jan-Feb TI - Rough vaccines in animal brucellosis: structural and genetic basis and present status. PG - 1-38 AB - Brucellosis control and eradication requires serological tests and vaccines. Effective classical vaccines (S19 in cattle and Rev 1 in small ruminants), however, induce antibodies to the O-polysaccharide of the lipopolysaccharide which may be difficult to distinguish from those resulting from infection and may thus complicate diagnosis. Rough attenuated mutants lack the O-polysaccharide and would solve this problem if eliciting protective immunity; the empirically obtained rough mutants 45/20 and RB51 have been used as vaccines. Strain 45/20 is reportedly unstable and it is not presently used. RB51 is increasingly used instead of S19 in some countries but it is rifampicin resistant and its effectiveness is controversial. Some controlled experiments have found good or absolute protection in adult cattle vaccinated orally (full dose) or subcutaneously (reduced dose) and in one field experiment, RB51 was reported to afford absolute protection to calves and to perform better than S19. Controlled experiments in calves, however, have shown reduced doses of RB51 to be ineffective, full doses only partially effective, and RB51 less effective than S19 against severe challenges. Moreover, other observations suggest that RB51 is ineffective when prevalence is high. RB51 is not useful in sheep and evidence in goats is preliminary and contradictory. Rough mutants obtained by molecular biology methods on the knowledge of the genetics and structure of Brucella lipopolysaccharide may offer alternatives. The B. abortus manBcore (rfbK) mutant seems promising in cattle, and analyses in mice suggest that mutations affecting only the O-polysaccharide result in better vaccines than those affecting both core and O-polysaccharide. Possible uses of rough vaccines also include boosting immunity by revaccination but solid evidence on its effectiveness, safety and practicality is not available. AD - Departamento de Microbiologia, Universidad de Navarra, Aptdo. 177, 31080 Pamplona, Spain. imoriyon@unav.es FAU - Moriyon, Ignacio AU - Moriyon I FAU - Grillo, Maria Jesus AU - Grillo MJ FAU - Monreal, Daniel AU - Monreal D FAU - Gonzalez, David AU - Gonzalez D FAU - Marin, Clara AU - Marin C FAU - Lopez-Goni, Ignacio AU - Lopez-Goni I FAU - Mainar-Jaime, Raul C AU - Mainar-Jaime RC FAU - Moreno, Edgardo AU - Moreno E FAU - Blasco, Jose Maria AU - Blasco JM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - France TA - Vet Res JT - Veterinary research JID - 9309551 RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Brucella/*genetics/*immunology MH - Brucella Vaccine/administration & dosage/*immunology MH - Brucella abortus/genetics/immunology MH - Brucellosis/prevention & control/*veterinary MH - Brucellosis, Bovine/*prevention & control MH - Cattle MH - Goats MH - Mice MH - Sheep MH - Swine RF - 138 EDAT- 2004/04/22 05:00 MHDA- 2004/10/01 05:00 CRDT- 2004/04/22 05:00 AID - 10.1051/vetres:2003037 [doi] AID - V4101 [pii] PST - ppublish SO - Vet Res. 2004 Jan-Feb;35(1):1-38. PMID- 15322336 OWN - NLM STAT- MEDLINE DA - 20040823 DCOM- 20041106 LR - 20061115 IS - 0385-5600 (Print) IS - 0385-5600 (Linking) VI - 48 IP - 8 DP - 2004 TI - Epidemiological and serological survey of brucellosis in Mongolia by ELISA using sarcosine extracts. PG - 571-7 AB - Brucellosis is an important zoonosis, and serological surveillance is essential to its control. However, cross-reactions of attenuated live cells of Brucella abortus strain S-19 and B. melitensis strain Rev-1 with Yersinia enterocolitica O9 or vaccinated animal sera interfere with accurate serological diagnosis by the Rose Bengal test (RBT). Therefore, we used ELISA with sarcosine extracts from the virulent B. abortus strain 544 to eliminate false-positives among RBT positive-sera. A total of 697 serum samples were collected in Mongolia from humans and animals in 23 nomadic herds. The herds were classified into three groups as brucellosis-endemic (BE), brucellosis-suspected (BS), or Brucella-vaccinated (BV). The number of 295 animals (43.0%) was positive by RBT, but 206 (69.8%) of these were positive according to ELISA; therefore, 30.2% of the RBT-positive sera were found to be false positives. The false positive samples for RTB represent 4.1%, 27.4%, and 68.2% of the animals from the BE, BS, and BV herds, respectively. In addition, 32% of RBT-positive human sera were also false positives. Thus, our ELISA would be more specific than RTB and useful for epidemiological surveillance for brucellosis. AD - Department of Applied Veterinary Science, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan. FAU - Erdenebaatar, Janchivdorj AU - Erdenebaatar J FAU - Bayarsaikhan, Balgan AU - Bayarsaikhan B FAU - Yondondorj, Agchbazar AU - Yondondorj A FAU - Watarai, Masahisa AU - Watarai M FAU - Shirahata, Toshikazu AU - Shirahata T FAU - Jargalsaikhan, Enkhtuya AU - Jargalsaikhan E FAU - Kawamoto, Keiko AU - Kawamoto K FAU - Makino, Sou-ichi AU - Makino S LA - eng PT - Evaluation Studies PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Japan TA - Microbiol Immunol JT - Microbiology and immunology JID - 7703966 RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 107-97-1 (Sarcosine) RN - 11121-48-5 (Rose Bengal) SB - IM MH - Animal Husbandry MH - Animals MH - Animals, Domestic/*microbiology MH - Antibodies, Bacterial/*blood MH - Antigens, Bacterial/*immunology/isolation & purification MH - Brucella abortus/*immunology MH - Brucellosis/diagnosis/*epidemiology/veterinary MH - Brucellosis, Bovine/diagnosis/epidemiology MH - Cattle MH - Humans MH - Mongolia/epidemiology MH - Rose Bengal MH - Sarcosine MH - Sensitivity and Specificity EDAT- 2004/08/24 05:00 MHDA- 2004/11/09 09:00 CRDT- 2004/08/24 05:00 AID - JST.JSTAGE/mandi/48.571 [pii] PST - ppublish SO - Microbiol Immunol. 2004;48(8):571-7. PMID- 15804600 OWN - NLM STAT- MEDLINE DA - 20050404 DCOM- 20050726 LR - 20081121 IS - 1043-4666 (Print) IS - 1043-4666 (Linking) VI - 30 IP - 2 DP - 2005 Apr 21 TI - Interferon-gamma associated cytokines and chemokines produced by spleen cells from Brucella-immune mice. PG - 86-92 AB - It is known that interferon (IFN)-gamma plays a critical role in protection against brucellosis. In this study we have investigated several cytokines and chemokines that are associated with IFN-gamma for potential in vitro correlates of protection. We cultured spleen cells in vitro from mice immunized orally with a live, attenuated Brucella melitensis vaccine candidate (WR201) and stimulated these cells with a lysate of B. melitensis. Differential gene expression of several cytokines and chemokines in stimulated spleen cells was analysed by real-time PCR, and secreted proteins were determined by ELISA. Immunized mice produced higher levels of both protein and gene transcripts for IFN-gamma, interleukin (IL)-2, IL-18 and MIP1-alpha. Immunized mice also had elevated gene expression levels for IL12-p40, IL23-p19, IP-10, MIG and MCP-1 when compared to normal mice. In this study we have identified new cytokines and chemokines as potential immune correlates in responses to protection in Brucella-vaccinated mice. AD - Department of Bacterial Diseases, Walter Reed Army Institute of Research, Bldg 503, Room 3E10, Robert Grant Avenue, Silver Spring, MD 20910, USA. chrysanthi.paranavitana@na.amedd.army.mil FAU - Paranavitana, Chrysanthi AU - Paranavitana C FAU - Zelazowska, Elzbieta AU - Zelazowska E FAU - Izadjoo, Mina AU - Izadjoo M FAU - Hoover, David AU - Hoover D LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Cytokine JT - Cytokine JID - 9005353 RN - 0 (Brucella Vaccine) RN - 0 (Chemokines) RN - 0 (Cytokines) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Animals MH - Brucella Vaccine/immunology MH - Brucella melitensis/*immunology MH - Brucellosis/prevention & control MH - Chemokines/*genetics/immunology/metabolism MH - Cytokines/*genetics/immunology/metabolism MH - Female MH - Gene Expression Regulation MH - Interferon-gamma/*genetics/metabolism MH - Mice MH - Mice, Inbred BALB C MH - Reference Values MH - Spleen/*immunology/metabolism MH - Vaccination EDAT- 2005/04/05 09:00 MHDA- 2005/07/27 09:00 CRDT- 2005/04/05 09:00 PHST- 2004/06/28 [received] PHST- 2004/11/30 [revised] PHST- 2004/12/17 [accepted] AID - S1043-4666(05)00028-1 [pii] AID - 10.1016/j.cyto.2004.12.009 [doi] PST - ppublish SO - Cytokine. 2005 Apr 21;30(2):86-92. PMID- 15899298 OWN - NLM STAT- MEDLINE DA - 20050518 DCOM- 20050721 LR - 20061115 IS - 0167-5877 (Print) IS - 0167-5877 (Linking) VI - 69 IP - 1-2 DP - 2005 Jun 10 TI - A model of animal-human brucellosis transmission in Mongolia. PG - 77-95 AB - We developed a dynamic model of livestock-to-human brucellosis transmission in Mongolia. The compartmental model considers transmission within sheep and cattle populations and the transmission to humans as additive components. The model was fitted to demographic and seroprevalence data (Rose Bengal test) from livestock and annually reported new human brucellosis cases in Mongolia for 1991-1999 prior to the onset of a mass livestock-vaccination campaign (S19 Brucella abortus for cattle and Rev 1 Brucella melitensis for sheep and goat). The vaccination effect was fitted to livestock- and human-brucellosis data from the first 3 years of the vaccination campaign (2000-2002). Parameters were optimized on the basis of the goodness-of-fit (assessed by the deviance). The simultaneously fitted sheep-human and cattle-human contact rates show that 90% of human brucellosis was small-ruminant derived. Average effective reproductive ratios for the year 1999 were 1.2 for sheep and 1.7 for cattle. AD - Swiss Tropical Institute, P.O. Box, CH-4002, Basle, Switzerland. jakob.zinsstag@unibas.ch FAU - Zinsstag, J AU - Zinsstag J FAU - Roth, F AU - Roth F FAU - Orkhon, D AU - Orkhon D FAU - Chimed-Ochir, G AU - Chimed-Ochir G FAU - Nansalmaa, M AU - Nansalmaa M FAU - Kolar, J AU - Kolar J FAU - Vounatsou, P AU - Vounatsou P LA - eng PT - Evaluation Studies PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Prev Vet Med JT - Preventive veterinary medicine JID - 8217463 SB - IM MH - Animals MH - Brucellosis/transmission/*veterinary MH - Cattle MH - Cattle Diseases/epidemiology/prevention & control/*transmission MH - Humans MH - *Models, Statistical MH - Mongolia/epidemiology MH - Sheep MH - Sheep Diseases/epidemiology/prevention & control/*transmission MH - Vaccination/veterinary MH - *Zoonoses EDAT- 2005/05/19 09:00 MHDA- 2005/07/22 09:00 CRDT- 2005/05/19 09:00 PHST- 2003/07/18 [received] PHST- 2005/01/25 [revised] PHST- 2005/01/25 [accepted] AID - S0167-5877(05)00057-7 [pii] AID - 10.1016/j.prevetmed.2005.01.017 [doi] PST - ppublish SO - Prev Vet Med. 2005 Jun 10;69(1-2):77-95. PMID- 16439039 OWN - NLM STAT- MEDLINE DA - 20060320 DCOM- 20061026 LR - 20061115 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 24 IP - 15 DP - 2006 Apr 5 TI - Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. PG - 2910-6 AB - The Brucella abortus S19 and RB51 strains are the most widely used live vaccines against bovine brucellosis. However, both can induce abortion and milk excretion, S19 vaccination interferes in serological tests, and RB51 is less effective. We have shown previously that a rough wbkAB. abortus mutant is attenuated and a better vaccine than RB51 in BALB/c mice, and that mutants in the two-component regulatory system bvrS/bvrR are markedly attenuated while keeping a smooth lipopolysaccharide (S-LPS). In this work, we tested whether simultaneous inoculation with live bvrS increases wbkA vaccine efficacy in mice. Even at high doses, the bvrS mutant was cleared much faster from spleens than the wbkA mutant. The splenic persistence of the wbkA mutant increased when inoculated along with the bvrS mutant, but also with inactivated bvrS cells or with purified B. abortus S-LPS, strongly suggesting that S-LPS in the bvrS mutant played a determinant role in the wbkA persistence. When inoculated alone, both mutants protected against virulent B. abortus but less than when inoculated simultaneously, and the protection afforded by the combination was better than that obtained with B. abortus S19. Increased protection was also obtained after simultaneous inoculation of the wbkA mutant and inactivated bvrS cells or purified S-LPS, showing again the role played by the S-LPS in the bvrS cells. In mice, the bvrS-wbkA combination induced an antibody response reduced with respect to B. abortus S19 vaccination. Thus, the simultaneous use of live bvrS and wbkA B. abortus mutants seems a promising approach to overcome the problems of the S19 andRB51 vaccines. AD - Centro de Investigacion y Tecnologia Agroalimentaria (CITA), Sanidad Animal, Gobierno de Aragon, Apartado 727, 50080 Zaragoza, Spain. mjgrillo@aragon.es FAU - Grillo, Maria Jesus AU - Grillo MJ FAU - Manterola, Lorea AU - Manterola L FAU - de Miguel, Maria Jesus AU - de Miguel MJ FAU - Munoz, Pilar Maria AU - Munoz PM FAU - Blasco, Jose Maria AU - Blasco JM FAU - Moriyon, Ignacio AU - Moriyon I FAU - Lopez-Goni, Ignacio AU - Lopez-Goni I LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060106 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Proteins) RN - 0 (Brucella Vaccine) RN - 0 (BvrR protein, Brucella) RN - 0 (BvrS protein, Brucella) RN - 0 (Lipopolysaccharides) RN - 0 (Vaccines, Attenuated) RN - 0 (Vaccines, Inactivated) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Bacterial Proteins/*genetics MH - Brucella Vaccine/administration & dosage/*immunology/isolation & purification MH - Brucella abortus/genetics/*immunology/pathogenicity MH - Brucellosis/*prevention & control MH - Colony Count, Microbial MH - Female MH - Lipopolysaccharides/administration & dosage/immunology/isolation & purification MH - Mice MH - Mice, Inbred BALB C MH - Mutation MH - Spleen/microbiology/pathology MH - Vaccines, Attenuated/administration & dosage/immunology MH - Vaccines, Inactivated/administration & dosage/immunology MH - Virulence/genetics EDAT- 2006/01/28 09:00 MHDA- 2006/10/27 09:00 CRDT- 2006/01/28 09:00 PHST- 2005/06/17 [received] PHST- 2005/11/24 [revised] PHST- 2005/12/19 [accepted] PHST- 2006/01/06 [aheadofprint] AID - S0264-410X(05)01287-9 [pii] AID - 10.1016/j.vaccine.2005.12.038 [doi] PST - ppublish SO - Vaccine. 2006 Apr 5;24(15):2910-6. Epub 2006 Jan 6. PMID- 17070627 OWN - NLM STAT- MEDLINE DA - 20061212 DCOM- 20070312 LR - 20081121 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 25 IP - 5 DP - 2007 Jan 15 TI - Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep. PG - 794-805 AB - The commonly used live attenuated vaccine in ovine brucellosis prophylaxis is Brucella melitensis Rev.1. This vaccine is known to induce antibody responses in vaccinated animals indistinguishable by the current conventional serological tests from those observed in challenged animals. Brucella BP26 and Omp31 proteins have shown an interesting potential as diagnostic antigens for ovine brucellosis. Accordingly, the bp26 gene and both bp26 and omp31 genes have been deleted from the vaccine strain Rev.1. Immunogenicity and vaccine efficacy of the parental Rev.1 strain and of both mutants in protecting sheep against B. melitensis strain H38 challenge was evaluated by clinical and bacteriological examination of ewes. They were conjunctivally or subcutaneously vaccinated when 4 months old and then challenged with B. melitensis H38 at the middle of the first pregnancy following vaccination. Deletion of bp26 and omp31 genes did not significantly affect the well recognised capacity of Rev.1 to protect sheep against B. melitensis challenge. However, the protection conferred by the CGV2631 mutant was significantly lower than that conferred by the CGV26 mutant or the Rev.1 strain. Vaccinated and challenged animals were detected positive in classical serological tests and in the IFN-gamma assay. A BP26-based ELISA was investigated to discriminate between ewes vaccinated by the mutants and ewes challenged with B. melitensis H38. The cut-off which was chosen in order to have 100% specificity resulted in a moderate sensitivity for the detection of challenged ewes. The use in the field of one of the mutants as vaccine against a B. melitensis infection, combined with classic diagnostic tests and a BP26 ELISA, could thus give an improvement in the differentiation between vaccinated and infected animals and contribute to the objective of eradication of brucellosis in small ruminants. AD - UR1282-Unite d'Infectiologie Animale et Sante Publique, Institut National de la Recherche Agronomique, Centre de Tours-Nouzilly, 37380 Nouzilly, France. isabelle.jacques@tours.inra.fr FAU - Jacques, Isabelle AU - Jacques I FAU - Verger, Jean-Michel AU - Verger JM FAU - Laroucau, Karine AU - Laroucau K FAU - Grayon, Maggy AU - Grayon M FAU - Vizcaino, Nieves AU - Vizcaino N FAU - Peix, Alvaro AU - Peix A FAU - Cortade, Fabienne AU - Cortade F FAU - Carreras, Florence AU - Carreras F FAU - Guilloteau, Laurence A AU - Guilloteau LA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060927 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (BP26 protein, Brucella) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Membrane Proteins) RN - 0 (Omp31 protein, Brucella melitensis) RN - 0 (Vaccines, Synthetic) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Animals MH - Bacterial Outer Membrane Proteins/*genetics MH - Brucella Vaccine/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/*prevention & control MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Gene Deletion MH - Interferon-gamma/biosynthesis MH - Membrane Proteins/*genetics MH - Milk/microbiology MH - Sheep MH - Vaccination MH - Vaccines, Synthetic/*immunology MH - Vagina/microbiology EDAT- 2006/10/31 09:00 MHDA- 2007/03/14 09:00 CRDT- 2006/10/31 09:00 PHST- 2006/05/15 [received] PHST- 2006/09/07 [revised] PHST- 2006/09/12 [accepted] PHST- 2006/09/27 [aheadofprint] AID - S0264-410X(06)01046-2 [pii] AID - 10.1016/j.vaccine.2006.09.051 [doi] PST - ppublish SO - Vaccine. 2007 Jan 15;25(5):794-805. Epub 2006 Sep 27. PMID- 17172046 OWN - NLM STAT- MEDLINE DA - 20061218 DCOM- 20090428 IS - 0001-6209 (Print) IS - 0001-6209 (Linking) VI - 46 IP - 5 DP - 2006 Oct TI - [The application and research advances of Brucella vaccines] PG - 856-9 AB - Brucellosis is a crucial zoonosis caused by Brucella, which has some traits of wide hosts, great infectivity and difficulty in cure. Brucellosis caused great losses to farming and people's health. Vaccination is the main measure used to control Brucellosis, and some attenuated Brucella strains were often used as vaccines. To find more effective vaccines, Scientists are now constructing recombinant strains, DNA vaccines and subunit vaccines, as well as inducing new attenuated strains from isolations. The present applications of B. abortus strain 19 (S19) , B. melitensis Rev. 1 (Rev. 1), B. suis strain 2 (S2), B. abortus strain 45/20 (45/20) and rough strain B. abortus 51 (RB51) were discussed. And some recent research work on Brucella vaccines, such as Brucella recombinant vaccines, DNA vaccines and so on, were reviewed in this paper. AD - China Institute of Veterinary Drug Control, Beijing 100081, China. dingjiabo@sohu.com FAU - Ding, Jia-Bo AU - Ding JB FAU - Mao, Kai-Rong AU - Mao KR FAU - Cheng, Jun-Sheng AU - Cheng JS FAU - Dai, Zhi-Hong AU - Dai ZH FAU - Jiang, Yu-Wen AU - Jiang YW LA - chi PT - English Abstract PT - Journal Article PT - Review PL - China TA - Wei Sheng Wu Xue Bao JT - Wei sheng wu xue bao = Acta microbiologica Sinica JID - 21610860R RN - 0 (Brucella Vaccine) RN - 0 (Recombinant Proteins) RN - 0 (Vaccines, Attenuated) RN - 0 (Vaccines, DNA) RN - 0 (Vaccines, Synthetic) SB - IM MH - Animals MH - Brucella Vaccine/*immunology MH - Humans MH - Recombinant Proteins/immunology MH - Vaccines, Attenuated/immunology MH - Vaccines, DNA/immunology MH - Vaccines, Synthetic/immunology RF - 26 EDAT- 2006/12/19 09:00 MHDA- 2009/04/29 09:00 CRDT- 2006/12/19 09:00 PST - ppublish SO - Wei Sheng Wu Xue Bao. 2006 Oct;46(5):856-9. PMID- 17216995 OWN - NLM STAT- MEDLINE DA - 20070112 DCOM- 20070201 IS - 0013-2446 (Print) IS - 0013-2446 (Linking) VI - 72 IP - 3-4 DP - 1997 TI - Immunological assay after vaccination of goats with Brucella melitensis Rev. I and Brucella abortus 45/20 vaccines at Saudi Arabia. PG - 379-94 AB - The living smooth Brucella melitensis Rev. I vaccine given in the normal dose (7x10(8) organism) to goats 3 to 5 months of age stimulated a marked increase in agglutinin titer. Fractionation of pools of serum by gel filtration by anion exchange chromatography, using diethylaminoethyl (DEAE -) cellulose showed that both IgM and IgG agglutinins were present from 12 to 47 days after goats were vaccinated. Only mercaptoethanol (ME)-sensitive agglutinins were detected in most goats 4 months after vaccination, but 2 of 30 goats retained ME-resistant agglutinins for the 13 1/2 - month observation period. Fractionation of serums from goats representative of these 2 types of serologic response indicated that most goats had only IgM agglutinins, whereas the 2 given goats had activity in the IgG fraction. Adult goats given Brucella abortus 42/20 adjuvant vaccine and revaccinated 5 months later developed low agglutination titers to smooth antigen, and all became test positive to the antiglobulin test. Fractionation of serum of pools taken 1 week and 8 months after revaccination indicated that antibody activity was restricted to the IgG fraction. Sera from 5 vaccinated and nonvaccinated goats which were positive by bacteriological culture examination at necropsy 31 to 47 days after goats were given conjunctival inoculation of virulent B. melitensis had antibody activity in both IgG and IgM fractions. Test positive reaction to the ME, complement-fixation (CF), and antiglobulin (AG) test were restricted to the IgG-containing fractions of serum, whereas reactions to the agglutination (STT) and the card tests appeared with either or both fractions. The effect of these findings on the choice of tests for the differentiation of vaccination response is discussed. AD - Faculty of Veterinary Medicine, Qassime, Saudi Arabia. FAU - Taher, S A AU - Taher SA FAU - Ewais, M A AU - Ewais MA LA - eng PT - Journal Article PL - Egypt TA - J Egypt Public Health Assoc JT - The Journal of the Egyptian Public Health Association JID - 7505602 RN - 0 (Bacterial Vaccines) RN - 0 (Immunoglobulins) RN - 0 (Rev.1 vaccine, Brucella melitensis) SB - IM MH - Animals MH - Bacterial Vaccines/administration & dosage/*immunology MH - Brucella abortus/immunology MH - Brucella melitensis/immunology MH - Brucellosis/*immunology/prevention & control/*veterinary MH - Goat Diseases/*immunology/prevention & control MH - Goats MH - Immunoglobulins/chemistry/isolation & purification/metabolism MH - Models, Animal MH - Vaccination/methods EDAT- 1997/01/01 00:00 MHDA- 2007/02/03 09:00 CRDT- 1997/01/01 00:00 PST - ppublish SO - J Egypt Public Health Assoc. 1997;72(3-4):379-94. PMID- 17459850 OWN - NLM STAT- MEDLINE DA - 20070426 DCOM- 20070621 IS - 1040-6387 (Print) IS - 1040-6387 (Linking) VI - 19 IP - 3 DP - 2007 May TI - Diagnostic characterization of a feral swine herd enzootically infected with Brucella. PG - 227-37 AB - Eighty feral swine were trapped from a herd that had been documented to be seropositive for Brucella and which had been used for Brucella abortus RB51 vaccine trials on a 7,100-hectare tract of land in South Carolina. The animals were euthanized and complete necropsies were performed. Samples were taken for histopathology, Brucella culture, and Brucella serology. Brucella was cultured from 62 (77.5%) animals. Brucella suis was isolated from 55 animals (68.8%), and all isolates were biovar 1. Brucella abortus was isolated from 28 animals (35.0%), and isolates included field strain biovar 1 (21 animals; 26.3%), vaccine strain Brucella abortus S19 (8 animals, 10.0%), and vaccine strain Brucella abortus RB51 (6 animals, 7.5%). Males were significantly more likely to be culture positive than females (92.9% vs. 60.6%). Thirty-nine animals (48.8%) were seropositive. Males also had a significantly higher seropositivity rate than females (61.9% vs. 34.2%). The relative sensitivity rates were significantly higher for the standard tube test (44.6%) and fluorescence polarization assay (42.6%) than the card agglutination test (13.1%). Lesions consistent with Brucella infection were commonly found in the animals surveyed and included inflammatory lesions of the lymph nodes, liver, kidney, and male reproductive organs, which ranged from lymphoplasmacytic to pyogranulomatous with necrosis. This is the first report of an apparent enzootic Brucella abortus infection in a feral swine herd suggesting that feral swine may serve as a reservoir of infection for Brucella abortus as well as Brucella suis for domestic livestock. AD - Bacterial Diseases of Livestock Research Unit, National Animal Disease Center, US Department of Agriculture, Ames, IA 50010, USA. bstoffre@nadc.ars.usda.gov FAU - Stoffregen, William C AU - Stoffregen WC FAU - Olsen, Steven C AU - Olsen SC FAU - Jack Wheeler, C AU - Jack Wheeler C FAU - Bricker, Betsy J AU - Bricker BJ FAU - Palmer, Mitchell V AU - Palmer MV FAU - Jensen, Allen E AU - Jensen AE FAU - Halling, Shirley M AU - Halling SM FAU - Alt, David P AU - Alt DP LA - eng PT - Journal Article PL - United States TA - J Vet Diagn Invest JT - Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc JID - 9011490 RN - 0 (Antibodies, Bacterial) RN - 0 (DNA, Bacterial) SB - IM MH - Agglutination Tests/veterinary MH - Animals MH - Animals, Wild MH - Antibodies, Bacterial/blood MH - Brucella/genetics/*isolation & purification MH - Brucellosis/blood/epidemiology/pathology/*veterinary MH - DNA, Bacterial/chemistry/genetics MH - Female MH - Fluorescence Polarization Immunoassay/veterinary MH - Histocytochemistry/veterinary MH - Male MH - Minisatellite Repeats/genetics MH - Polymerase Chain Reaction/veterinary MH - Sequence Analysis, DNA MH - Seroepidemiologic Studies MH - South Carolina/epidemiology MH - Swine MH - Swine Diseases/blood/epidemiology/*microbiology/pathology MH - Zoonoses/microbiology EDAT- 2007/04/27 09:00 MHDA- 2007/06/22 09:00 CRDT- 2007/04/27 09:00 AID - 19/3/227 [pii] PST - ppublish SO - J Vet Diagn Invest. 2007 May;19(3):227-37. PMID- 18164561 OWN - NLM STAT- MEDLINE DA - 20080513 DCOM- 20081104 IS - 0378-1135 (Print) IS - 0378-1135 (Linking) VI - 129 IP - 3-4 DP - 2008 Jun 22 TI - Evaluation of Brucella abortus DNA and RNA vaccines expressing Cu-Zn superoxide dismutase (SOD) gene in cattle. PG - 396-403 AB - This study was conducted to evaluate the immunogenicity of a DNA or RNA vaccines encoding Brucella abortus Cu-Zn superoxide dismutase (SOD) in cattle. Intramuscular injection of plasmid DNA carrying Brucella SOD gene (pcDNA-SOD) into animals elicited both humoral and cellular immune responses. Animals injected with pcDNA-SOD developed SOD IgG antibody with predominance of immunoglobulin G1 (IgG1) isotype over IgG2. In addition, the DNA vaccine elicited a specific T-cell-proliferative response. Furthermore, intraperitoneal injection of cattle with recombinant Semliki Forest virus particles carrying recombinant RNA encoding SOD (SFV-SOD) did not lead to the induction of SOD IgG 1 or 2 antibody, but induced specific T-cell activation. Both vaccines were able to induce a non-significant secretion of gamma interferon and did not induce the secretion of IL-4 or tumor necrosis factor (TNF)-alpha. These results suggest that SOD gene in a genetic vaccine formulation (DNA or RNA) might be of potential us as a vaccine to induce cell-mediated immunity in cattle. To our knowledge, this is the first study to evaluate a genetic vaccine against Brucella in cattle. AD - Molecular Immunology Laboratory, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepcion, Concepcion, Chile. FAU - Saez, Darwin AU - Saez D FAU - Guzman, Ingrid AU - Guzman I FAU - Andrews, Edilia AU - Andrews E FAU - Cabrera, Alex AU - Cabrera A FAU - Onate, Angel AU - Onate A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20071122 PL - Netherlands TA - Vet Microbiol JT - Veterinary microbiology JID - 7705469 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (RNA, recombinant) RN - 0 (Vaccines, DNA) RN - 63231-63-0 (RNA) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - Animals, Newborn MH - Antibodies, Bacterial/biosynthesis MH - Antibody Formation MH - Brucella Vaccine/administration & dosage/*immunology MH - Brucella abortus/enzymology/genetics/*immunology MH - Brucellosis, Bovine/*prevention & control MH - Cattle MH - Female MH - Immunity, Cellular MH - RNA/*immunology MH - Random Allocation MH - Superoxide Dismutase/genetics/*immunology/metabolism MH - Vaccines, DNA/administration & dosage/*immunology EDAT- 2008/01/01 09:00 MHDA- 2008/11/05 09:00 CRDT- 2008/01/01 09:00 PHST- 2007/10/10 [received] PHST- 2007/11/13 [revised] PHST- 2007/11/15 [accepted] PHST- 2007/11/22 [aheadofprint] AID - S0378-1135(07)00570-6 [pii] AID - 10.1016/j.vetmic.2007.11.015 [doi] PST - ppublish SO - Vet Microbiol. 2008 Jun 22;129(3-4):396-403. Epub 2007 Nov 22. PMID- 18359093 OWN - NLM STAT- MEDLINE DA - 20080519 DCOM- 20080909 IS - 0165-2427 (Print) IS - 0165-2427 (Linking) VI - 123 IP - 3-4 DP - 2008 Jun 15 TI - Improved performance of Brucella melitensis native hapten over Brucella abortus OPS tracer on goat antibody detection by the fluorescence polarization assay. PG - 223-9 AB - The current method for goat brucellosis diagnosis is based on the World Organization for Animal Health (OIE) using the screening card test (CT), with antigen at 8% (CT8) or 3% (CT3) of cell concentrations, and the confirmatory complement fixation test (CFT). However, these tests do not differentiate antibodies induced by vaccination from those derived from field infections by Brucella species or other bacterial agents; in places like Mexico, where the prevalence of brucellosis and the vaccination rates are high, there is a considerable percentage of false positive reactions that causes significant unnecessary slaughter of animals. Furthermore, results of the fluorescence polarization assay (FPA) using the Brucella abortus O-polysaccharide (OPS) tracer in goats are poorer than those with cattle. The present study was undertaken to investigate a tracer prepared from the native hapten (NH) of the Rev. 1 strain of Brucella melitensis to improve FPA performance on goat brucellosis diagnosis. Evaluation of 48 positive samples and 96 negative samples showed that the NH tracer was more accurate (p<0.01) than the OPS tracer (97.2% vs. 93.8% accuracy, respectively). On the diagnostic performance evaluation, the NH tracer performed better (87.5% accuracy, 79.5% sensitivity, 84.3% specificity, and 163.8 performance index) than the OPS tracer (83.5%, 75.9%, 81.0%, and 156.9, respectively) using 1009 positive and 2039 negative Mexican field goat sera samples selected by test series approved by the OIE (card test 3% and CFT). We demonstrated a new application for the NH lipopolysaccharide on detecting antibodies against Brucella using the FPA, which may yield faster results (minutes vs. 24-72h) than the immunodiagnosis assays frequently used in bovine brucellosis. In addition, NH tracer produces similar or better performance results than the conventional OPS tracer, using the FPA in goat sera samples. AD - Instituto Nacional de Investigaciones Forestales y Agropecuarias, Campo Experimental Rio Bravo, Rio Bravo, Tamaulipas, Mexico. FAU - Ramirez-Pfeiffer, C AU - Ramirez-Pfeiffer C FAU - Diaz-Aparicio, E AU - Diaz-Aparicio E FAU - Rodriguez-Padilla, C AU - Rodriguez-Padilla C FAU - Morales-Loredo, A AU - Morales-Loredo A FAU - Alvarez-Ojeda, G AU - Alvarez-Ojeda G FAU - Gomez-Flores, R AU - Gomez-Flores R LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080216 PL - Netherlands TA - Vet Immunol Immunopathol JT - Veterinary immunology and immunopathology JID - 8002006 RN - 0 (Antibodies, Bacterial) RN - 0 (Fluorescent Dyes) RN - 0 (Haptens) RN - 3326-32-7 (Fluorescein-5-isothiocyanate) SB - IM MH - Animals MH - Antibodies, Bacterial/*blood/immunology MH - Brucella abortus/immunology MH - Brucella melitensis/chemistry/*immunology MH - Brucellosis/diagnosis/immunology/microbiology/*veterinary MH - Cattle MH - Fluorescein-5-isothiocyanate/chemistry MH - Fluorescence Polarization Immunoassay/methods/*veterinary MH - Fluorescent Dyes/chemistry MH - Goat Diseases/blood/diagnosis/immunology/*microbiology MH - Goats MH - Haptens/*chemistry/immunology MH - ROC Curve MH - Reproducibility of Results MH - Sensitivity and Specificity EDAT- 2008/03/25 09:00 MHDA- 2008/09/10 09:00 CRDT- 2008/03/25 09:00 PHST- 2007/03/22 [received] PHST- 2008/01/22 [revised] PHST- 2008/02/08 [accepted] PHST- 2008/02/16 [aheadofprint] AID - S0165-2427(08)00062-7 [pii] AID - 10.1016/j.vetimm.2008.02.001 [doi] PST - ppublish SO - Vet Immunol Immunopathol. 2008 Jun 15;123(3-4):223-9. Epub 2008 Feb 16. PMID- 18405337 OWN - NLM STAT- MEDLINE DA - 20080414 DCOM- 20080710 IS - 1865-1674 (Print) VI - 55 IP - 3-4 DP - 2008 May TI - A study on the use of male animal models for developing a live vaccine for brucellosis. PG - 145-51 AB - To study the safety of Brucella melitensis WR201, a live vaccine candidate, we compared the course of infection of this strain with that of virulent 16M in male BALB/c mice. At various times after oral immunization with strains WR201 or 16M, lungs, liver, spleen, testis, epididymis, inguinal and cervical lymph nodes were removed. Tissues were divided for microbiologic culture and histopathological examination. WR201 infection in male BALB/c mice had lower intensity and shorter duration than infection caused by virulent 16M. Pathological examination of testis and epididymis revealed no inflammation following strain WR201 immunization. In contrast, animals given virulent 16M strain had substantial inflammation in infected tissues. These data confirm the marked attenuation of WR201 relative to 16M. In addition, these studies suggest that male mice may be useful to assess the safety of live, attenuated Brucella vaccine candidates. AD - Department of Environmental and Infectious Disease Sciences, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA. izadjoo@afip.osd.mil FAU - Izadjoo, M J AU - Izadjoo MJ FAU - Mense, M G AU - Mense MG FAU - Bhattacharjee, A K AU - Bhattacharjee AK FAU - Hadfield, T L AU - Hadfield TL FAU - Crawford, R M AU - Crawford RM FAU - Hoover, D L AU - Hoover DL LA - eng PT - Journal Article PL - Germany TA - Transbound Emerg Dis JT - Transboundary and emerging diseases JID - 101319538 RN - 0 (Brucella Vaccine) RN - 0 (Brucella melitensis 16M conjugate vaccine) RN - 0 (Serum Albumin, Bovine) RN - 0 (Vaccines, Attenuated) SB - IM MH - Administration, Oral MH - Animals MH - Brucella Vaccine/administration & dosage/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/pathology/prevention & control/*veterinary MH - Disease Models, Animal MH - Male MH - Mice MH - Mice, Inbred BALB C MH - Random Allocation MH - Serum Albumin, Bovine MH - Vaccination/*veterinary MH - Vaccines, Attenuated EDAT- 2008/04/15 09:00 MHDA- 2008/07/11 09:00 CRDT- 2008/04/15 09:00 AID - JVA1019 [pii] AID - 10.1111/j.1865-1682.2008.01019.x [doi] PST - ppublish SO - Transbound Emerg Dis. 2008 May;55(3-4):145-51. PMID- 18727806 OWN - NLM STAT- MEDLINE DA - 20080827 DCOM- 20080929 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 14 IP - 8 DP - 2008 Aug TI - Occupational infection due to Brucella abortus S19 among workers involved in vaccine production in Argentina. PG - 805-7 AB - The pathological consequences of exposure to the vaccine strain Brucella abortus S19 were evaluated in 30 employees from vaccine-manufacturing plants. Active brucellosis was diagnosed in 21 subjects, of whom only five recalled an accidental exposure. Clinical manifestations were mild, and only one patient presented a complication. After antimicrobial therapy, initially symptomatic patients either experienced clinical remission or had mild persistent symptoms. This is the first study reporting infection by B. abortus S19 among workers from vaccine-manufacturing plants, which in many cases was acquired from unnoticed exposures. Measures to improve the safety of B. abortus S19 handling should be implemented. AD - Hospital F. J. Muniz, Buenos Aires. FAU - Wallach, J C AU - Wallach JC FAU - Ferrero, M C AU - Ferrero MC FAU - Victoria Delpino, M AU - Victoria Delpino M FAU - Fossati, C A AU - Fossati CA FAU - Baldi, P C AU - Baldi PC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - France TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) SB - IM MH - Adult MH - Antibodies, Bacterial/blood MH - Argentina/epidemiology MH - *Brucella Vaccine MH - Brucella abortus/*immunology/isolation & purification MH - Brucellosis/*diagnosis/epidemiology/physiopathology MH - Drug Industry/*methods MH - Female MH - Humans MH - *Laboratory Personnel MH - Male MH - Middle Aged MH - *Occupational Exposure EDAT- 2008/08/30 09:00 MHDA- 2008/09/30 09:00 CRDT- 2008/08/30 09:00 AID - CLM2029 [pii] AID - 10.1111/j.1469-0691.2008.02029.x [doi] PST - ppublish SO - Clin Microbiol Infect. 2008 Aug;14(8):805-7. PMID- 18980780 OWN - NLM STAT- MEDLINE DA - 20081229 DCOM- 20090320 IS - 0165-2427 (Print) IS - 0165-2427 (Linking) VI - 127 IP - 1-2 DP - 2009 Jan 15 TI - Evaluation of three different antigens in an indirect enzyme-linked immunoassay for the detection of antibodies against Brucella abortus SRB51 in vaccinated heifers. PG - 153-5 AB - The live attenuated Brucella abortus SRB51 (SRB51) is a partial O-chain-deprived mutant. The relative lack of the polysaccharide prevents it from inducing antibodies detectable by most of the serological tests used for the diagnosis of bovine brucellosis. The performance of three antigens used in an indirect enzyme-linked immunoassay test for detecting SRB51 antibodies were evaluated. A homogeneous group of twenty-five 10-month-old Hereford heifers was used. The animals were bled on day 0 and then subcutaneously vaccinated with 2 ml of a commercially available SRB51 vaccine (Schering-Plough) containing 1x10(7) to 3.4x10(7) viable cells. Blood samples without anticoagulant for sera obtaining were then collected at days 30, 90, 210 and 360 post-vaccination. To detect the SRB51 antibodies, Brucella ovis hot saline extract, B. ovis RLPS (RLPS), and SRB51-RLPS were used. The buffered antigen plate agglutination test and an indirect enzyme-linked immunoassay (I-ELISA) using the smooth LPS (SLPS) antigen from B. abortus were used as control tests. All the sera samples were negative in the BPA test and in the standard I-ELISA using the SLPS. The SRB51-RLPS and the B. ovis RLPS antigens performed better than the B. ovis hot saline extract antigen. AD - Animal Health Unit, The National Institute for Agricultural Technology (INTA), Bariloche, Argentina. crobles@bariloche.inta.gov.ar FAU - Robles, C A AU - Robles CA FAU - Nielsen, K AU - Nielsen K FAU - Gall, D AU - Gall D FAU - Willems, P AU - Willems P LA - eng PT - Comparative Study PT - Evaluation Studies PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080919 PL - Netherlands TA - Vet Immunol Immunopathol JT - Veterinary immunology and immunopathology JID - 8002006 RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Lipopolysaccharides) SB - IM MH - Agglutination Tests/methods/veterinary MH - Animals MH - Antibodies, Bacterial/*blood MH - *Antigens, Bacterial MH - Brucella Vaccine/administration & dosage/*immunology MH - Brucella abortus/*immunology MH - Brucellosis, Bovine/immunology/prevention & control MH - Cattle MH - Enzyme-Linked Immunosorbent Assay/methods/*veterinary MH - Female MH - Lipopolysaccharides/immunology EDAT- 2008/11/05 09:00 MHDA- 2009/03/21 09:00 CRDT- 2008/11/05 09:00 PHST- 2007/09/11 [received] PHST- 2008/08/02 [revised] PHST- 2008/09/12 [accepted] PHST- 2008/09/19 [aheadofprint] AID - S0165-2427(08)00348-6 [pii] AID - 10.1016/j.vetimm.2008.09.007 [doi] PST - ppublish SO - Vet Immunol Immunopathol. 2009 Jan 15;127(1-2):153-5. Epub 2008 Sep 19. PMID- 19007836 OWN - NLM STAT- MEDLINE DA - 20081216 DCOM- 20090317 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 27 IP - 2 DP - 2009 Jan 7 TI - Efficacy of bp26 and bp26/omp31 B. melitensis Rev.1 deletion mutants against Brucella ovis in rams. PG - 187-91 AB - Brucella melitensis Rev.1 is the most effective vaccine against B. ovis infection in sheep but induces antibodies interfering with B. melitensis diagnosis. Brucella BP26 and Omp31 proteins are differential diagnostic antigens. Single or double bp26 and omp31 Rev.1 deletion mutants have been proven effective against B. melitensis in sheep. Here, the CGV26 (deleted in bp26 gene) and CGV2631 (deleted in both bp26 and omp31 genes) mutants have been tested for efficacy against B. ovis in rams. Either inoculated subcutaneously or conjunctivally, both mutants conferred significant protection against B. ovis. The protection induced by CGV26 was similar to that of Rev.1 but significantly higher than that conferred by CGV2631. In conclusion, the CGV26 mutant, in association with the adequate diagnostic strategy, could be a useful alternative to Rev.1 for sheep vaccination against B. ovis infections in those countries performing simultaneously B. melitensis and B. ovis eradication campaigns. AD - Instituto de Agrobiotecnologia, CSIC-UPNA-Gobierno de Navarra, Carretera de Mutilva, s/n. 31192, Mutilva Baja, Navarra, Spain. mariajesus.grillo@unavarra.es FAU - Grillo, M J AU - Grillo MJ FAU - Marin, C M AU - Marin CM FAU - Barberan, M AU - Barberan M FAU - de Miguel, M J AU - de Miguel MJ FAU - Laroucau, K AU - Laroucau K FAU - Jacques, I AU - Jacques I FAU - Blasco, J M AU - Blasco JM LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20081111 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (BP26 protein, Brucella) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Bacterial Vaccines) RN - 0 (Membrane Proteins) RN - 0 (Omp31 protein, Brucella melitensis) RN - 0 (Rev.1 vaccine, Brucella melitensis) SB - IM MH - Animals MH - Bacterial Outer Membrane Proteins/*genetics MH - Bacterial Vaccines/*administration & dosage/genetics/immunology MH - Brucella melitensis/genetics/immunology MH - Brucella ovis/*immunology MH - Brucellosis/microbiology/prevention & control/*veterinary MH - *Gene Deletion MH - Immunization/veterinary MH - Male MH - Membrane Proteins/*genetics MH - Mutation MH - Sheep MH - Sheep Diseases/immunology/microbiology/*prevention & control MH - Treatment Outcome EDAT- 2008/11/15 09:00 MHDA- 2009/03/18 09:00 CRDT- 2008/11/15 09:00 PHST- 2008/09/12 [received] PHST- 2008/10/16 [revised] PHST- 2008/10/21 [accepted] PHST- 2008/11/11 [aheadofprint] AID - S0264-410X(08)01455-2 [pii] AID - 10.1016/j.vaccine.2008.10.065 [doi] PST - ppublish SO - Vaccine. 2009 Jan 7;27(2):187-91. Epub 2008 Nov 11. PMID- 19186196 OWN - NLM STAT- MEDLINE DA - 20090303 DCOM- 20090515 IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 27 IP - 11 DP - 2009 Mar 10 TI - Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. PG - 1741-9 AB - Classical brucellosis vaccines induce antibodies to the O-polysaccharide section of the lipopolysaccharide that interfere in serodiagnosis. Brucella rough (R) mutants lack the O-polysaccharide but their usefulness as vaccines is controversial. Here, Brucella melitensis R mutants in all main lipopolysaccharide biosynthetic pathways were evaluated in sheep in comparison with the reference B. melitensis Rev 1 vaccine. In a first experiment, these mutants were tested for ability to induce anti-O-polysaccharide antibodies, persistence and spread through target organs, and innocuousness. Using the data obtained and those of genetic studies, three candidates were selected and tested for efficacy as vaccines against a challenge infecting 100% of unvaccinated ewes. Protection by R vaccines was 54% or less whereas Rev 1 afforded 100% protection. One-third of R mutant vaccinated ewes became positive in an enzyme-linked immunosorbent assay with smooth lipopolysaccharide due to the core epitopes remaining in the mutated lipopolysaccharide. We conclude that R vaccines interfere in lipopolysaccharide immunosorbent assays and are less effective than Rev 1 against B. melitensis infection of sheep. AD - INRA, UR1282, Infectiologie Animale et Sante Publique, IASP, Nouzilly F-37380, France. FAU - Barrio, Maria B AU - Barrio MB FAU - Grillo, Maria J AU - Grillo MJ FAU - Munoz, Pilar M AU - Munoz PM FAU - Jacques, Isabelle AU - Jacques I FAU - Gonzalez, David AU - Gonzalez D FAU - de Miguel, Maria J AU - de Miguel MJ FAU - Marin, Clara M AU - Marin CM FAU - Barberan, Montserrat AU - Barberan M FAU - Letesson, Jean-J AU - Letesson JJ FAU - Gorvel, Jean-P AU - Gorvel JP FAU - Moriyon, Ignacio AU - Moriyon I FAU - Blasco, Jose M AU - Blasco JM FAU - Zygmunt, Michel S AU - Zygmunt MS LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090130 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (Bacterial Vaccines) RN - 0 (Lipopolysaccharides) SB - IM MH - Animals MH - Antibodies, Bacterial/*biosynthesis MH - Bacterial Vaccines/*immunology MH - Brucella melitensis/*immunology MH - Brucellosis/*immunology/*veterinary MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Freeze Drying MH - Lipopolysaccharides/*biosynthesis/*genetics MH - Macrophages/microbiology MH - Male MH - Mice MH - Mutation/immunology MH - Pregnancy MH - Sheep MH - Sheep Diseases/*immunology MH - Vaccination EDAT- 2009/02/03 09:00 MHDA- 2009/05/16 09:00 CRDT- 2009/02/03 09:00 PHST- 2008/10/29 [received] PHST- 2008/12/30 [revised] PHST- 2009/01/11 [accepted] PHST- 2009/01/30 [aheadofprint] AID - S0264-410X(09)00063-2 [pii] AID - 10.1016/j.vaccine.2009.01.025 [doi] PST - ppublish SO - Vaccine. 2009 Mar 10;27(11):1741-9. Epub 2009 Jan 30. PMID- 19204348 OWN - NLM STAT- MEDLINE DA - 20090210 DCOM- 20090427 IS - 0090-3558 (Print) IS - 0090-3558 (Linking) VI - 45 IP - 1 DP - 2009 Jan TI - Experimental infection of Richardson's ground squirrels (Spermophilus richardsonii) with attenuated and virulent strains of Brucella abortus. PG - 189-95 AB - A previous investigation of the safety of Brucella abortus strain RB51 (sRB51) in various nontarget species suggested that Richardson's ground squirrels (Spermophilus richardsonii) may develop persistent infections when orally inoculated with the vaccine. In the present study, sRB51, B. abortus strain 19 (s19), and virulent B. abortus strain 9941 (s9941) were administered orally to Richardson's ground squirrels to further characterize B. abortus infection in this species. Six groups of nongravid ground squirrels were orally inoculated with 6 x 10(8) colony forming units (cfu) sRB51 (n = 10), 2.5 x 10(4) cfu s19 (n = 10), 2.5 x 10(7) cfu s19 (n = 6), 1.3 x 10(6) cfu s9941 (n = 5), 2.1 x 10(8) cfu s9941 (n = 5), or vaccine diluent (control; n = 4). One of five animals in the lower-dose s19 group and two of three animals in the higher-dose s19 group showed persistence of bacteria in various tissues at 14 wk postinoculation (PI). At 18 wk PI, one of five animals in the sRB51 group and one of five animals in the high-dose s9941 group were culture positive. Although we did detect some persistence of B. abortus strains at 18 wk, we found no evidence of pathology caused by B. abortus strains in nonpregnant Richardson's ground squirrels based on clinical signs, gross lesions, and microscopic lesions. AD - US Department of Agriculture (USDA), Animal and Plant Health Inspection Service, National Wildlife Research Center, 4101 LaPorte Avenue, Fort Collins, Colorado 80521, USA. pauline.nol@aphis.usda.gov FAU - Nol, Pauline AU - Nol P FAU - Olsen, Steven C AU - Olsen SC FAU - Rhyan, Jack C AU - Rhyan JC LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - J Wildl Dis JT - Journal of wildlife diseases JID - 0244160 RN - 0 (Brucella Vaccine) SB - IM MH - Administration, Oral MH - Animals MH - Animals, Wild/microbiology MH - Brucella Vaccine/*administration & dosage MH - Brucella abortus/*pathogenicity MH - Brucellosis/immunology/microbiology/prevention & control/*veterinary MH - Colony Count, Microbial/veterinary MH - Female MH - Male MH - Rodent Diseases/immunology/*microbiology/prevention & control MH - Safety MH - Sciuridae/*microbiology MH - Species Specificity MH - Treatment Outcome MH - Virulence EDAT- 2009/02/11 09:00 MHDA- 2009/04/28 09:00 CRDT- 2009/02/11 09:00 AID - 45/1/189 [pii] PST - ppublish SO - J Wildl Dis. 2009 Jan;45(1):189-95. PMID- 19293473 OWN - NLM STAT- MEDLINE DA - 20090318 DCOM- 20090716 IS - 1735-1383 (Print) VI - 6 IP - 1 DP - 2009 Mar TI - Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model. PG - 12-21 AB - BACKGROUND: The immunogenic Brucella abortus ribosomal protein L7/L12 is a promising candidate antigen for the development of subunit vaccines against brucellosis. OBJECTIVE: This study was aimed to evaluate the protection of recombinant Human Serum Albumin (HAS)-L7/L12 fusion protein in Balb/c mice. METHODS: The amplified L7/L12 gene was cloned in pYHSA5 vector, pYHSA5-L7/L12 construct was transformed in Saccharomyces cerevisiae and the expressed protein from supernatant was purified by affinity chromatography. Balb/c mice were immunized in five groups by tHSA-L7/L12 fusion protein (group 1), Brucella abortus S19 (group 2), HSA (group 3), recombinant L7/L12 (group 4), PBS (group 5). ELISA to detect antibody production, LTT test to assess antigen specific lymphocyte response were conducted prior to virulent B. abortus strain 544 challenge two weeks after the last injection. Bacterial counts from spleens of immunized mice were done four weeks after challenge. RESULTS: In ELISA tests, the specific antibodies exhibited a dominance of immunoglobulin IgG1 over IgG2a. In addition, the tHSA-L7/L12 fusion protein and L7/L12 elicited a strong T-cell proliferative response upon restimulation in vitro with recombinant tHSA-L7/L12 and L7/L12, suggesting the induction of a cellular immunity response in vivo. However, there was no significant difference in proliferative response of L7/L12 and tHSA-L7/L12 fusion protein (p>0.05). The L7/L12 and tHSA-L7/L12 fusion protein vaccines could also induce significant protection against challenge with the virulent strain B. abortus 544 in Balb/c mice (p< or =0.05). CONCLUSION: The tHSA-L7/L12 fusion protein, similar to L7/L12 has the ability to induce antigen specific lymphocyte proliferation, stimulate humoral immunity and engender protection. AD - Department of Microbiology, Ilam University of Medical Sciences, Ilam, Iran. pakzad_i2006@yahoo.com FAU - Pakzad, Iraj AU - Pakzad I FAU - Rezaee, Abbas AU - Rezaee A FAU - Rasaee, Mohammad Javad AU - Rasaee MJ FAU - Tabbaraee, Bahman AU - Tabbaraee B FAU - Delpisheh, Ali AU - Delpisheh A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Iran TA - Iran J Immunol JT - Iranian journal of immunology : IJI JID - 101282932 RN - 0 (Bacterial Proteins) RN - 0 (Immunoglobulin G) RN - 0 (Recombinant Fusion Proteins) RN - 0 (Ribosomal Proteins) RN - 0 (Serum Albumin) RN - 70815-33-7 (ribosomal protein L7-L12) SB - IM MH - Animals MH - Antibody Formation/immunology MH - Bacterial Proteins/genetics/*immunology MH - Brucella abortus/genetics/*immunology MH - Brucellosis/microbiology/prevention & control MH - Female MH - Genetic Vectors/genetics MH - Humans MH - Immunity, Cellular/immunology MH - Immunoglobulin G/blood/immunology MH - Lymphocyte Activation/immunology MH - Mice MH - Mice, Inbred BALB C MH - *Models, Animal MH - Recombinant Fusion Proteins/biosynthesis/genetics/*immunology MH - Ribosomal Proteins/genetics/*immunology MH - Saccharomyces cerevisiae/genetics/metabolism MH - Serum Albumin/genetics/*immunology MH - Spleen/cytology/immunology/microbiology MH - T-Lymphocytes/immunology MH - Vaccination EDAT- 2009/03/19 09:00 MHDA- 2009/07/17 09:00 CRDT- 2009/03/19 09:00 AID - 02 [pii] AID - IJIv6i1A2 [doi] PST - ppublish SO - Iran J Immunol. 2009 Mar;6(1):12-21. PMID- 19362381 OWN - NLM STAT- MEDLINE DA - 20090520 DCOM- 20090728 LR - 20091026 IS - 1873-1716 (Electronic) IS - 0167-5877 (Linking) VI - 90 IP - 1-2 DP - 2009 Jul 1 TI - Shedding of Brucella abortus rough mutant strain RB51 in milk of water buffalo (Bubalus bubalis). PG - 113-8 AB - The objective of this study was to determine if Brucella abortus rough mutant strain RB51 (SRB51) is eliminated in buffalo milk. Thirty Brucella-free female buffaloes were used in this study: ten 4-5 years old were inoculated with the triple of the recommended calfhood dose of SRB51 by subcutaneous route, ten 2-3 years old at the first lactation were previously vaccinated twice as calves with triple the recommended calf dose of RB51, while five 4-5 years old and five 2-3 years old not vaccinated Brucella-free female buffaloes served as controls. Milk samples were taken aseptically on a daily basis for the first 30 days and weekly for the second and third months. The samples were inoculated on selective media for isolation of SRB51 and incubated for 11 days. Moreover, PCR analysis was also performed directly on milk samples. SRB51 was isolated from milk samples only during the first week post-vaccination while RB51 DNA was detected during the first week till the fourth week post-vaccination only in water buffaloes vaccinated as adults. The identification of Brucella RB51 in milk samples, strongly suggests that this Brucella vaccine could be excreted in milk of buffalo cows vaccinated as adults, while our data demonstrate that the vaccine is safe for use in buffaloes vaccinated as calves in which it was not excreted in milk. AD - Department of Pathology and Animal Health, University of Naples Federico II, via F. Delpino 1, Naples 80137, Italy. FAU - Longo, Mariangela AU - Longo M FAU - Mallardo, Karina AU - Mallardo K FAU - Montagnaro, Serena AU - Montagnaro S FAU - De Martino, Luisa AU - De Martino L FAU - Gallo, Sergio AU - Gallo S FAU - Fusco, Giovanna AU - Fusco G FAU - Galiero, Giorgio AU - Galiero G FAU - Guarino, Achille AU - Guarino A FAU - Pagnini, Ugo AU - Pagnini U FAU - Iovane, Giuseppe AU - Iovane G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090411 PL - Netherlands TA - Prev Vet Med JT - Preventive veterinary medicine JID - 8217463 RN - 0 (Brucella Vaccine) SB - IM MH - Age Factors MH - Animals MH - Animals, Newborn MH - Brucella Vaccine/*administration & dosage MH - Brucella abortus/genetics/immunology/*isolation & purification MH - Brucellosis/epidemiology/immunology/prevention & control/*veterinary MH - Buffaloes/immunology/*microbiology MH - Colony Count, Microbial/veterinary MH - Female MH - Milk/*microbiology MH - Mutation MH - Polymerase Chain Reaction/veterinary MH - Vaccination/veterinary EDAT- 2009/04/14 09:00 MHDA- 2009/07/29 09:00 CRDT- 2009/04/14 09:00 PHST- 2008/10/13 [received] PHST- 2009/03/05 [revised] PHST- 2009/03/14 [accepted] PHST- 2009/04/11 [aheadofprint] AID - S0167-5877(09)00060-9 [pii] AID - 10.1016/j.prevetmed.2009.03.007 [doi] PST - ppublish SO - Prev Vet Med. 2009 Jul 1;90(1-2):113-8. Epub 2009 Apr 11. PMID- 19439382 OWN - NLM STAT- MEDLINE DA - 20090520 DCOM- 20090728 LR - 20091026 IS - 1873-1716 (Electronic) IS - 0167-5877 (Linking) VI - 90 IP - 1-2 DP - 2009 Jul 1 TI - Eradication of bovine brucellosis in the Azores, Portugal-Outcome of a 5-year programme (2002-2007) based on test-and-slaughter and RB51 vaccination. PG - 80-9 AB - Bovine brucellosis is an important contagious disease that can cause abortions and infertility in cattle, and can be transmitted to humans. Despite having an eradication programme in place since 1994, in 2000 the situation of bovine brucellosis due to Brucella abortus was not significantly improving in 3 of the 9 islands (Terceira, S. Miguel and S. Jorge) of the archipelago of Azores, an autonomous region of Portugal. Farming on these islands, particularly dairy, is extensive. Therefore, the use of RB51 vaccine, which does not induce antibodies detectable with routine brucellosis diagnostic tests, was implemented. This article reports the results of an eradication programme based on RB51 mass vaccination combined with test-and-slaughter, which was implemented in the Azores during the 2002-2007 period. During the first round of vaccination, both adult cows and heifers were vaccinated. Subsequently, only replacement stock aged 4-12 months, were immunized with RB51.The test-and-slaughter policy based on bulk milk ring test (MRT) and serological surveillance was maintained. During this period, the average brucellosis herd incidence, herd prevalence and individual prevalence decreased 69.26%, 39.26% and 75.41% respectively for the three above-mentioned islands. However, disease reduction approaching eradication was obtained only on the island of Terceira, where a high level of vaccine coverage was rapidly reached and regularly maintained together with strict application of a test-and-slaughter programme. This work shows that the RB51 vaccine could be a useful tool for eradicating bovine brucellosis in well-controlled epidemiological units provided that there is mass vaccine coverage for a sufficiently long period of time and it is combined with an appropriate test-and-slaughter programme. AD - DRDA, Vinha Brava, Angra do Heroismo 9700-861, Portugal. FAU - Martins, H AU - Martins H FAU - Garin-Bastuji, B AU - Garin-Bastuji B FAU - Lima, F AU - Lima F FAU - Flor, L AU - Flor L FAU - Pina Fonseca, A AU - Pina Fonseca A FAU - Boinas, F AU - Boinas F LA - eng PT - Journal Article DEP - 20090512 PL - Netherlands TA - Prev Vet Med JT - Preventive veterinary medicine JID - 8217463 RN - 0 (Antibodies, Bacterial) RN - 0 (Brucella Vaccine) SB - IM MH - Animals MH - Antibodies, Bacterial/*blood MH - Brucella Vaccine/*administration & dosage MH - Brucella abortus/*immunology MH - Brucellosis, Bovine/epidemiology/*prevention & control MH - Cattle MH - Euthanasia, Animal MH - Female MH - Male MH - Portugal/epidemiology MH - Prevalence MH - Vaccination/*veterinary EDAT- 2009/05/15 09:00 MHDA- 2009/07/29 09:00 CRDT- 2009/05/15 09:00 PHST- 2008/03/15 [received] PHST- 2009/04/01 [revised] PHST- 2009/04/07 [accepted] PHST- 2009/05/12 [aheadofprint] AID - S0167-5877(09)00084-1 [pii] AID - 10.1016/j.prevetmed.2009.04.002 [doi] PST - ppublish SO - Prev Vet Med. 2009 Jul 1;90(1-2):80-9. Epub 2009 May 12. PMID- 19596411 OWN - NLM STAT- MEDLINE DA - 20090803 DCOM- 20090917 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 27 IP - 38 DP - 2009 Aug 20 TI - Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella. PG - 5214-9 AB - This study describes the potential use of attenuated Salmonella enterica serovar Typhimurium Strains (S. typhimurium) to express and deliver a L7/L12 and BLS fusion antigen of Brucella as a vaccination strategy to prevent Brucella infection in mice. S. typhimurium X4072 that contained a pTrc99A-BLS-L7/L12 plasmid, designated X4072bl, can deliver a L7/L12 and BLS fusion antigen expressed by the bacterium itself, while S. typhimurium X4550 that contained an asd-pVAX1-BLS-L7/L12 (asd-pBL) plasmid, designated X4550bl, can deliver the antigen to be expressed in target eukaryotic cells. When orally administered to BALB/c mice, both attenuated carrier strains were able to elicit mucosal and systemic immunity, which induced protection against B. abortus 544 infection in mice. The immunogenicity and protective efficacy of X4072bl and X4550bl were compared with a recombinant BLS-L7/L12 fusion protein vaccine (rBL) and a pVAX1-BLS-L7/L12 DNA vaccine (pBL) in this study. When rBL and pBL were intramuscularly injected into mice, both vaccines could also elicit comparable humoral and cellular immune responses, but not mucosal immunity, which therefore induced lower protection. Taken together, Salmonella-based subunit vaccines are a promising vaccine strategy in the prevention of Brucella infection. AD - State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology & Epidemiology, Beijing 100071, China. FAU - Zhao, Zhongpeng AU - Zhao Z FAU - Li, Min AU - Li M FAU - Luo, Deyan AU - Luo D FAU - Xing, Li AU - Xing L FAU - Wu, Shuo AU - Wu S FAU - Duan, Yueqiang AU - Duan Y FAU - Yang, Penghui AU - Yang P FAU - Wang, Xiliang AU - Wang X LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090709 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 0 (Brucella Vaccine) RN - 0 (Recombinant Proteins) RN - 0 (Vaccines, DNA) RN - 0 (Vaccines, Subunit) SB - IM MH - Animals MH - Antibodies, Bacterial/blood MH - Antigens, Bacterial/*immunology MH - Brucella/*immunology MH - Brucella Vaccine/*immunology MH - Brucellosis/immunology/*prevention & control MH - Female MH - Immunity, Cellular MH - Immunity, Mucosal MH - Mice MH - Mice, Inbred BALB C MH - Plasmids MH - Recombinant Proteins/immunology MH - Salmonella typhimurium/*immunology MH - Spleen/cytology/immunology MH - Vaccines, DNA/immunology MH - Vaccines, Subunit/immunology EDAT- 2009/07/15 09:00 MHDA- 2009/09/18 06:00 CRDT- 2009/07/15 09:00 PHST- 2009/03/28 [received] PHST- 2009/06/21 [revised] PHST- 2009/06/22 [accepted] PHST- 2009/07/09 [aheadofprint] AID - S0264-410X(09)00951-7 [pii] AID - 10.1016/j.vaccine.2009.06.075 [doi] PST - ppublish SO - Vaccine. 2009 Aug 20;27(38):5214-9. Epub 2009 Jul 9. PMID- 19748579 OWN - NLM STAT- MEDLINE DA - 20091102 DCOM- 20091224 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 27 IP - 48 DP - 2009 Nov 12 TI - The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams. PG - 6704-11 AB - We have engineered the polymeric vaccine BLSOmp31 by decorating the highly immunogenic and decameric Brucella lumazine synthase with an exposed loop of the Brucella outer membrane protein Omp31. In the present study, we have immunized different groups of rams with the recombinant chimera rBLSOmp31 in two different adjuvants (Incomplete Freund Adjuvant-IFA and QUIL A) and with the plasmid pCIBLSOmp31 administered either by i.m. injection alone or by using electroporation. In addition, we have used a heterologous prime-boost strategy consisting of repeated pCIBLSOmp31 electroporation priming followed by a single protein boost. Both, chimera rBLSOmp31 in IFA and the prime-boost strategy induced the highest IgG specific antibodies with bacteriolytic activity. While electroporation-enhanced humoral immune responses as compared to pCIBLSOmp31 injection alone, the highest levels of specific IFN-gamma and protection against bacterial challenge were achieved with prime-boost (76%) and chimera rBLSOmp31 in IFA (63%). Taken together these results strongly support the usefulness of the chimera BLSOmp31 as a vaccine against Brucella ovis in ovine brucellosis. AD - Departamento de Sanidad Animal y Medicina Preventiva, Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil, Argentina. silmares@vet.unicen.edu.ar FAU - Estein, Silvia M AU - Estein SM FAU - Fiorentino, Maria A AU - Fiorentino MA FAU - Paolicchi, Fernando A AU - Paolicchi FA FAU - Clausse, Maria AU - Clausse M FAU - Manazza, Jorge AU - Manazza J FAU - Cassataro, Juliana AU - Cassataro J FAU - Giambartolomei, Guillermo H AU - Giambartolomei GH FAU - Coria, Lorena M AU - Coria LM FAU - Zylberman, Vanesa AU - Zylberman V FAU - Fossati, Carlos A AU - Fossati CA FAU - Kjeken, Rune AU - Kjeken R FAU - Goldbaum, Fernando A AU - Goldbaum FA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090911 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antibodies, Bacterial) RN - 0 (Antigens, Bacterial) RN - 0 (Bacterial Outer Membrane Proteins) RN - 0 (Brucella Vaccine) RN - 0 (Immunoglobulin G) RN - 0 (Lipids) RN - 0 (Multienzyme Complexes) RN - 0 (Recombinant Proteins) RN - 0 (Saponins) RN - 0 (incomplete Freund's adjuvant) RN - 66594-14-7 (Quil A) RN - 82115-62-6 (Interferon-gamma) RN - 89287-46-7 (6,7-dimethyl-8-ribityllumazine synthase) RN - 9007-36-7 (Complement System Proteins) RN - 9007-81-2 (Freund's Adjuvant) SB - IM MH - Adjuvants, Immunologic/administration & dosage MH - Agglutination Tests MH - Animals MH - Antibodies, Bacterial/blood MH - Antigens, Bacterial/*immunology MH - Bacterial Outer Membrane Proteins/*immunology MH - Brucella Vaccine/*immunology MH - Brucella ovis/immunology MH - Brucellosis/immunology/prevention & control/*veterinary MH - Complement System Proteins/immunology MH - Electroporation MH - Freund's Adjuvant/immunology MH - Immunity, Humoral MH - Immunoglobulin G/blood MH - Interferon-gamma/immunology MH - Lipids/immunology MH - Male MH - Multienzyme Complexes/immunology MH - Plasmids MH - Recombinant Proteins/immunology MH - Saponins/immunology MH - Sheep MH - Sheep Diseases/*immunology/prevention & control EDAT- 2009/09/15 06:00 MHDA- 2009/12/25 06:00 CRDT- 2009/09/15 06:00 PHST- 2009/07/15 [received] PHST- 2009/08/24 [revised] PHST- 2009/08/25 [accepted] PHST- 2009/09/11 [aheadofprint] AID - S0264-410X(09)01306-1 [pii] AID - 10.1016/j.vaccine.2009.08.097 [doi] PST - ppublish SO - Vaccine. 2009 Nov 12;27(48):6704-11. Epub 2009 Sep 11. PMID- 20124603 OWN - NLM STAT- In-Data-Review DA - 20100203 IS - 1735-1502 (Print) IS - 1735-1502 (Linking) VI - 8 IP - 3 DP - 2009 Sep TI - DNAs from Brucella Strains Activate Efficiently Murine Immune System with Production of Cytokines, Reactive Oxygen and Nitrogen Species. PG - 127-34 AB - Brucellosis is an infectious disease with high impact on innate immune responses which is induced partly by its DNA. In the present study the potential differences of wild type and patients isolates versus attenuated vaccine strains in terms of cytokines, ROS and NO induction on murine splenocytes and peritoneal macrophages were investigated. This panel varied in base composition and included DNA from B. abortus, B. melitensis, B.abortus strain S19 and melitensis strain Rev1, as attenuated live vaccine. Also we included Escherichia coli DNA, calf thymus DNA (a mammalian DNA), as controls. These DNA were evaluated for their ability to stimulate IL-12, TNF-alpha, IL-10, IFN-gamma and ROS production from spleenocytes as well as NO production from peritoneal macrophages. Spleen cells were cultured in 24 well at a concentration of 106 cells/ ml with subsequent addition of 10 mug/ml of Brucella or Ecoli DNAs. These cultures were incubated at 37 masculineC with 5% CO2 for 5 days. Supernatants were harvested and cytokines, ROS and NOx were evaluated. It was observed that TNF-alpha was induced in days 1,3,5 by all Brucella strains DNAs and E. coli DNA, IL-10 only was induced in day 1, IFN- gamma was induced only in day 5 and IL-12 not induced. ROS and NOx were produced by all strains; however, we observed higher production of NOx which were stimulated by DNA of B. melitensis. AD - Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. ardestani@ibb.ut.ac.ir. FAU - Tavakoli, Zahra AU - Tavakoli Z FAU - Ardestani, Sussan K AU - Ardestani SK FAU - Lashkarbolouki, Taghi AU - Lashkarbolouki T FAU - Kariminia, Amina AU - Kariminia A FAU - Zahraei Salehi, Taghi AU - Zahraei Salehi T FAU - Tavassoli, Nasser AU - Tavassoli N LA - eng PT - Journal Article PL - Iran TA - Iran J Allergy Asthma Immunol JT - Iranian journal of allergy, asthma, and immunology JID - 101146178 SB - IM EDAT- 2010/02/04 06:00 MHDA- 2010/02/04 06:00 CRDT- 2010/02/04 06:00 AID - 0803127134 [pii] AID - 08.03/ijaai.127134 [doi] PST - ppublish SO - Iran J Allergy Asthma Immunol. 2009 Sep;8(3):127-34. PMID- 20147498 OWN - NLM STAT- In-Process DA - 20100401 IS - 1556-679X (Electronic) IS - 1556-679X (Linking) VI - 17 IP - 4 DP - 2010 Apr TI - Evaluation of indirect enzyme-linked immunosorbent assays and IgG avidity assays using a protein A-peroxidase conjugate for serological distinction between Brucella abortus S19-vaccinated and -infected cows. PG - 588-95 AB - This study aimed to evaluate the use of protein A-peroxidase (horseradish peroxidase [HRPO]) in indirect enzyme-linked immunosorbent assays (iELISAs) and IgG avidity assays for serological distinction between Brucella abortus S19-vaccinated and -infected cows. Four groups were analyzed: GI, 41 nonvaccinated seropositive cows; GII, 79 S19-vaccinated heifers analyzed at 3 months postvaccination; GIII, 105 S19-vaccinated cows analyzed after 24 months of age; and GIV, 278 nonvaccinated seronegative cows. IgG levels and avidity to B. abortus smooth lipopolysaccharide (S-LPS) were determined using anti-bovine IgG-HRPO or protein A-HRPO conjugates. Similar levels of IgG anti-S-LPS were found with GI using both conjugates. Lower IgG levels were detected with GII, GIII, and GIV using protein A-HRPO. Both conjugates showed high performance in discriminating GI from GIII, with high sensitivity (Se; 97.6%) and specificity (Sp; 97.1%). Protein A-HRPO was better in distinguishing GI from GIV (Se, 97.6%; Sp, 94.6%) and GI from GII (Se, 80.5%; Sp, 94.9%). Protein A-HRPO excluded a higher number of positive samples with GII and GIV. IgG avidity showed that protein A-HRPO, but not anti-IgG-HRPO, was able to distinguish nonvaccinated from vaccinated cattle, showing a higher avidity index (AI) with GI than with GII, with 78% of serum samples in GII showing an AI of <50%. Therefore, the iELISA using B. abortus S-LPS antigen and protein A-HRPO conjugate for preferential detection of the IgG2 subclass was shown to be suitable for serological distinction between S19-vaccinated and -infected cows. Also, antibodies generated after vaccination showed lower avidity, suggesting a role for the IgG2 subclass as an antibody of higher-affinity maturation after infection, constituting an additional tool for differentiating vaccinated from infected cattle. AD - Laboratory of Immunoparasitology, Institute of Biomedical Sciences, Federal University of Uberlandia, 38400-902 Uberlandia, MG, Brazil FAU - Pajuaba, Ana C A M AU - Pajuaba AC FAU - Silva, Deise A O AU - Silva DA FAU - Mineo, Jose R AU - Mineo JR LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100210 PL - United States TA - Clin Vaccine Immunol JT - Clinical and vaccine immunology : CVI JID - 101252125 SB - IM PMC - PMC2849348 EDAT- 2010/02/12 06:00 MHDA- 2010/02/12 06:00 CRDT- 2010/02/12 06:00 PMCR- 2010/10/01 PHST- 2010/02/10 [aheadofprint] AID - CVI.00444-09 [pii] AID - 10.1128/CVI.00444-09 [doi] PST - ppublish SO - Clin Vaccine Immunol. 2010 Apr;17(4):588-95. Epub 2010 Feb 10. PMID- 20362622 OWN - NLM STAT- Publisher DA - 20100405 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) DP - 2010 Mar 31 TI - Attenuation of defined Brucella melitensiswboA mutants. AB - Rough Brucella mutants have been sought as vaccine candidates because they do not induce seroconversion. In this study, two defined nonreverting rough mutants were derived from virulent Brucella melitensis strain 16M: a wboA deletion mutant designated WRR51 and a wboApurEK dual deletion mutant designated WRRP1. Strain WRRP1 exhibited reduced survival in human monocyte-derived macrophages (hMDMs) compared with parent strain WRR51 or with DeltapurEK strain WR201. Strain WRRP1 persisted for 1 week or less in BALB/c mice after intraperitoneal infection, while less severe attenuation was exhibited by the two single mutants in this model. Trans complementation of wboA restored the survival of WRR51 in hMDMs comparable to strain 16M and the survival of WRRP1 comparable to strain WR201. CI - Copyright (c) 2010. Published by Elsevier Ltd. AD - Walter Reed Army Institute of Research, Division of Bacterial & Rickettsial Diseases, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA. AU - Nikolich MP AU - Warren RL AU - Lindler LE AU - Izadjoo MJ AU - Hoover DL LA - ENG PT - JOURNAL ARTICLE DEP - 20100331 TA - Vaccine JT - Vaccine JID - 8406899 EDAT- 2010/04/07 06:00 MHDA- 2010/04/07 06:00 CRDT- 2010/04/06 06:00 PHST- 2010/03/18 [received] PHST- 2010/03/19 [accepted] AID - S0264-410X(10)00458-5 [pii] AID - 10.1016/j.vaccine.2010.03.058 [doi] PST - aheadofprint SO - Vaccine. 2010 Mar 31.